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ABSTRACT 
Standard endovascular treatment of intracranial saccular aneurysms has been 
shown to be an effective treatment method, but it remains marked by aneurysm 
recanalization despite continued development of new device technologies. Polyurethane-
based shape memory polymer (SMP) foams are advantageous biomaterials for 
endovascular embolization applications, however previously developed devices utilizing 
SMP foam for neurovascular embolization treatment were limited by required catheter 
sizes, insufficient flexibility and radiopacity, and inconsistent device stability within the 
aneurysm sac. 
Solvent-stimulated actuation of hydrophobic SMP foams using DMSO and EtOH 
was shown to be an effective alternative shape memory trigger to direct heating. Dramatic 
decreases in Tg were observed with exposure to water, DMSO, and EtOH. Rapid shape 
recovery and volume swelling were observed for SMP foams in high concentrations of 
both DMSO and EtOH, as well as in decreased concentrations of EtOH. 
A SMP foam-over-wire (FOW) neurovascular embolization device was evaluated 
using in vitro and in vivo saccular aneurysm models as an initial prototype design. In vivo 
porcine aneurysms were successfully occluded using FOW devices with theoretical 
volume occlusion values greater than reported values for predicate devices and rapid, 
stable thrombus formation. FOW devices were successful in treating sidewall aneurysm 
models, though the study suggested a need to improve the deliverability and radiopacity 
of the devices and to evaluate the occlusion effectiveness in more clinically relevant 
aneurysm geometries. 
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A SMP foam-coated coil (FCC) embolization device was designed and 
demonstrated clinician-familiar deliverability and use combined with large packing 
density and scaffolding capability of porous SMP foam. Excellent cytocompatibility is a 
promising early result in showing biocompatibility. FCC devices exhibited smooth 
delivery, but difficult packing in both benchtop and rabbit elastase aneurysm models 
highlights the need to improving device stiffness. However, though packing in rabbit 
aneurysms was poor, the tissue response suggests a desired healing process and a 
promising indication that the more effectively packed FCC devices will prompt stable, 
long-term tissue healing. Overall, the device designed through this work demonstrates 
excellent potential for improving long-term clinical outcomes for patients with intracranial 
saccular aneurysms, whether ruptured or unruptured. 
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NOMENCLATURE 
aSAH Aneurysmal subarachnoid hemorrhage 
DI Water Deionized water 
DMA Dynamic mechanical analysis 
DMSO Dimethyl sulfoxide 
DSA Digital subtraction angiography 
DSC Differential scanning calorimetry 
EtOH Ethyl alcohol 
FCC Foam-coated-coil 
FOW Foam-over-wire 
GDC Guglielmi detachable coil 
H&E Hemotoxylin and eosin 
HPED N,N,N’,N’-Tetrakis(2-hydroxypropyl)ethylenediamine 
ID Inner diameter 
IPA Isopropyl alcohol 
IPDI Isophorone diisocyanate 
Nitinol Nickel titanium alloy 
OD Outer diameter 
PTAH Phosphotungstic acid haematoxylin 
PDMS Poly(dimethylsiloxane) 
Pt Platinum 
RO Water Reverse osmosis water 
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SMP Shape memory polymer 
TEA Triethanolamine 
Tg Glass transition temperature 
Ttrans Transition temperature 
W Tungsten 
 
x 
TABLE OF CONTENTS 
Page 
ABSTRACT ...................................................................................................................... ii 
DEDICATION ..................................................................................................................iv 
ACKNOWLEDGEMENTS ............................................................................................... v 
NOMENCLATURE ........................................................................................................ viii 
TABLE OF CONTENTS ................................................................................................... x 
LIST OF FIGURES ......................................................................................................... xii 
LIST OF TABLES ........................................................................................................ xvii 
CHAPTER I  INTRODUCTION AND LITERATURE REVIEW ................................... 1 
1.1 Intracranial Saccular Aneurysms ............................................................................. 1 
1.2 Endovascular Coiling Treatment .............................................................................. 2 
1.3 Shape Memory Polymer Foams ............................................................................... 5 
1.4 Rationale for Using Organic Solvents for SMP Actuation ...................................... 8 
1.5 Rationale for a SMP Foam-Coated Coil Device Design ........................................ 11 
CHAPTER II  SOLVENT STIMULATED ACTUATION OF POLYURETHANE-
BASED SHAPE MEMORY POLYMER FOAMS USING DIMETHYL 
SULFOXIDE AND ETHANOL ...................................................................................... 15 
2.1 Introduction ............................................................................................................ 15 
2.2 Materials and Methods ........................................................................................... 17 
2.3 Results and Discussion ........................................................................................... 22 
2.4 Conclusion .............................................................................................................. 34 
CHAPTER III  IN VITRO AND IN VIVO EVALUATION OF A SHAPE MEMORY 
POLYMER FOAM-OVER-WIRE EMBOLIZATION DEVICE DELIVERED IN 
SACCULAR ANEURYSM MODELS ............................................................................ 36 
3.1 Introduction ............................................................................................................ 36 
3.2 Materials and Methods ........................................................................................... 38 
3.3 Results .................................................................................................................... 48 
3.4 Discussion .............................................................................................................. 54 
3.5 Conclusions ............................................................................................................ 58 
xi 
CHAPTER IV  IN VITRO AND IN VIVO PERFORMANCE OF A SHAPE 
MEMORY POLYMER FOAM-COATED COIL EMBOLIZATION DEVICE ............ 59 
4.1 Introduction ............................................................................................................ 59 
4.2 Materials and Methods ........................................................................................... 61 
4.3 Results and Discussion ........................................................................................... 70 
4.4 Conclusions ............................................................................................................ 84 
CHAPTER V CONCLUSIONS ....................................................................................... 86 
5.1 Summary ................................................................................................................ 86 
5.2 Significance of Work ............................................................................................. 88 
5.3 Challenges and Future Directions .......................................................................... 90 
REFERENCES ................................................................................................................. 93 
 xii 
 
LIST OF FIGURES 
 Page 
Figure 1.1: Saccular aneurysms post-treatment using GDCs® and bioactive polymer-
coated coils. (A) DSA of loosely packed (empty arrow) bioactive polymer-
coated coils immediately post-embolization. Contrast is visible at small 
neck remnant (arrow) and throughout aneurysm. (B) DSA of tightly packed 
GDCs® immediately post-embolization. (C) Angiography of tightly packed 
GDCs® immediately post-embolization with small neck remnant (arrow). 
(D) Angiography of loosely packed (arrow) bioactive polymer-coated coils 
immediately post-embolization. (Adapted from [11] with permission from 
JNS Publishing Group) ....................................................................................... 3 
Figure 1.2: The shape memory cycle for a thermo-responsive shape memory polymer. 
(1) Heating above Ttrans. (2) Deforming to programmed geometry while T > 
Ttrans. (3) Cooling below Ttrans while holding programmed shape. (4) 
Heating above Ttrans to recover original shape. ................................................... 6 
Figure 1.3: Representative cell structure of foams for all the formulations H80 
through H40. Foams of all formulations show a mixed, closed to open cell 
structure, with thin cell membranes between struts. All scale bars are 500 
µm. (Adapted from [33] with permission from John Wiley and Sons) .............. 7 
Figure 1.4: Example of SMP transition temperature (Ttrans) change in response to 
contact with water or other solvents. .................................................................. 9 
Figure 1.5: H&E Staining (1× and 4× magnification): (A.90) 1× H&E staining of a 
bisected aneurysm after 90 days of implantation, (B.90) 4× H&E staining of 
the central core (square) of the bisected aneurysm after 90 days of 
implantation, and (C.90) 4× H&E staining of foam and parent artery 
interface (star) after 90 days of implantation. All scale bars are 1 mm. 
(Adapted from [1] with permission from John Wiley & Sons) ........................ 12 
Figure 2.1: SEM images of SMP foams. Foam pores in the transverse direction are 
shown on the top row for (a) 0IPDI, (b) 10IPDI, and (c) 20IPDI 
compositions. Foam pores in the axial direction are shown on the bottom 
row for (d) 0IPDI, (e) 10IPDI, and (f) 20IPDI compositions. .......................... 23 
Figure 2.2: Actuation of 20IPDI foam immersed in varying solvents at 37 °C, 
demonstrated with measurements of storage modulus over time normalized 
to the initial modulus value. .............................................................................. 27 
 xiii 
 
Figure 2.3: Actuation of varying SMP foam compositions immersed in 37 °C EtOH, 
demonstrated with measurements of storage modulus over time normalized 
to the initial modulus value. .............................................................................. 27 
Figure 2.4: Swelling volume ratio in 37 °C solvent solutions. Volume ratio is shown 
over time of submersion in (a) DMSO and (b) EtOH. ..................................... 28 
Figure 2.5: Volume recovery in 37 °C DMSO solutions. Volume recovery is shown 
over time of submersion in DMSO solutions of varying concentrations for 
SMP foam compositions of (a) 0IPDI, (b) 10IPDI, and (c) 20IPDI, where 
0% DMSO is 100% RO water. Note the break in the Time axis between 5 
and 10 min. ....................................................................................................... 30 
Figure 2.6: Volume recovery in 37 °C EtOH solutions. Volume recovery is shown 
over time of submersion in EtOH solutions of varying concentrations for 
SMP foam compositions of (a) 0IPDI, (b) 10IPDI, and (c) 20IPDI, where 
0% EtOH is 100% RO water. Note the break in the Time axis between 5 
and 10 min. ....................................................................................................... 31 
Figure 2.7: Images of 20IPDI actuation in 37 °C EtOH solutions. (a), (b), (c), and (d) 
show 20IPDI actuation in 100% EtOH at 0, 1, 2, and 5 min, respectively. 
(e), (f), (g) and (h) show 20IPDI actuation in 20% EtOH at 0, 5, 10, and 20 
min, respectively. .............................................................................................. 32 
Figure 3.1: Schematic diagrams of the SMP foam-over-wire (top panel), the delivery 
and detachment device (middle panel), and the laser heating mechanism 
(bottom panel). .................................................................................................. 39 
Figure 3.2: FOW embolization device. A) The threaded device prior to radial 
compression and attachment to the delivery and detachment device. Scale is 
mm. B) The assembled embolization device with compressed FOW device 
attached to the delivery and detachment device. .............................................. 40 
Figure 3.3: In vitro flow system schematic. The solid line indicates the simulated 
artery flow through the PDMS aneurysm model. The dashed line indicates 
the isothermal bath flow. .................................................................................. 43 
Figure 3.4: SMP foam expansion using simulated passive and active actuation 
methods. ............................................................................................................ 48 
Figure 3.5: FOW device in vitro delivery. A) Aneurysm model prior to device 
delivery. B-E) Delivery of four devices into the aneurysm model. F) 
Aneurysm model is well occluded. ................................................................... 49 
 xiv 
 
Figure 3.6: Heating profile of three different laser heating devices each tested three 
times. ................................................................................................................. 50 
Figure 3.7: FOW device treatment of porcine sidewall aneurysms labeled A, B, C, 
and D. Top Row: Digital subtraction angiography prior to device 
implantation. Bottom Row: Digital subtraction angiography after 
implantation of FOW devices. .......................................................................... 52 
Figure 3.8: Laser heated injection for increased SMP foam expansion. A) 
Fluoroscopic image prior to balloon inflation and ICG-doped saline 
injection. Digital subtraction angiography of treated aneurysm prior to (B) 
and after (C) laser heated injection. .................................................................. 53 
Figure 3.9: Explanted porcine sidewall aneurysm model. A) Digital subtraction 
angiography of the aneurysm prior to treatment. B) Digital subtraction 
angiography of the aneurysm after implantation of four FOW devices. C) 
Explanted aneurysm including parent vessel. D) Visualization of the 
explanted aneurysm neck. E) Partial removal of the explanted aneurysm 
wall. F) Thrombus with the implanted devices is stable after removal from 
the aneurysm. Scale is mm. .............................................................................. 54 
Figure 4.1: SMP foam-coated coil embolization device. (A) FCC device, 6x10 size, 
prior to radial compression. (B) FCC device, 6x10 size, after radial 
compression. (C) FCC device, 6x10 size, after expansion in 37 °C water for 
30 min. .............................................................................................................. 62 
Figure 4.2: Tortuous path for ease of delivery and working time testing. The distal tip 
of the FCC implant is placed at (A) the entry of the tortuous path to start 
ease of delivery testing. The device is advanced until the junction to the 
delivery wire reaches (B) to end ease of delivery testing. ................................ 64 
Figure 4.3: SMP foam shape recovery. Average diameter and standard deviation of 
three FCC devices are shown over time submerged in 37 °C RO water. The 
dashed line represents the inner diameter (ID) of the microcatheter used in 
subsequent tests. ............................................................................................... 70 
Figure 4.4: Microcatheter tip deflection during device deployment. Average angle of 
deflection and standard deviation are shown for five FCC and three control 
devices. Length deployed indicates the length of device deployed out of the 
microcatheter tip. .............................................................................................. 72 
Figure 4.5: Ease of delivery through tortuous pathway. Average delivery force is 
shown over the travel distance through the tortuous pathway for five FCC 
devices and three control devices. Standard deviations are shown every 0.9 
 xv 
 
cm of travel distance. A moving average over 2 mm travel distance was 
applied to the delivery force data. ..................................................................... 73 
Figure 4.6: Delivery forces during working time assessment. Delivery force for five 
FCC devices is shown over the submersion time as samples were deployed 
out and retracted into the microcatheter. Positive force indicates retraction, 
and negative force indicates deployment. The black arrows indicate that 
buckling of the delivery wire proximal to the microcatheter hub had 
occurred on the previous deploy cycle, causing no implant motion and no 
subsequent retraction on the indicated cycle. A moving average over 0.5 s 
submersion time was applied to the delivery force data. .................................. 74 
Figure 4.7: Cytocompatibility of FCC devices by neutral red uptake assay. Cell 
viability of 3T3 fibroblasts is shown for FCC devices compared to blank 
and control groups. Average viability of six wells is shown with standard 
deviation for each extract concentration. .......................................................... 76 
Figure 4.8: FCC device deployment into in vitro aneurysm model. (A) Aneurysm 
model prior to device deployment. Air bubbles in the system are visible. (B) 
First FCC device deployment. (C) Second FCC device deployment. (D) 
Third FCC device deployment. (E) Packed aneurysm model 30 min after 
implant of the third device. (F) Reverse side of packed aneurysm model 30 
min after implant of third device. ..................................................................... 77 
Figure 4.9: Digital subtraction angiography (DSA) images of the aneurysms prior to 
and after treatment. The top row shows DSA images of aneurysm A prior to 
treatment (A), after treatment (A.0), and 30 days after treatment (A.30), 
where white arrows indicate the edge of contrast infiltration through the 
neck and into the dome of the aneurysm. The middle row shows DSA 
images of aneurysm B prior to treatment (B), after treatment (B.0), and 30 
days after treatment (B.30), where white arrows indicate the edge of 
contrast infiltration through the neck and into the dome of the aneurysm and 
black arrows indicate a section of an implanted device left in the parent 
artery after premature detachment occurred. The bottom row shows DSA 
images of aneurysm C prior to treatment (C), after treatment (C.0), and 30 
days after treatment (C.30), where white arrows indicate the edge of 
contrast infiltration through the neck and into the dome of the aneurysm. ...... 80 
Figure 4.10: Images of H&E stained and sectioned slides from histological analysis at 
various magnification. The top row shows slide images of aneurysm A at 
12.5x (A-12.5x), 40x (A-40x), and 100x (A-100x) magnification. The black 
arrow indicates the eosinophilic SMP foam material, and the white arrow 
indicates where the Axium coil was positioned, though the coil was 
removed during sectioning. The middle row shows slide images of  
 xvi 
 
aneurysm B at 12.5x (B-12.5x), 40x (B-40x), and 100x (B-100x) magnification. The 
black arrow indicates the connective tissue within and surrounding the coil within the 
parent artery, and the white arrow indicates the endothelial and neointima layer at the 
interface between the connective tissue in the dome and the neck remnant. The 
bottom row shows slide images of aneurysm C at 12.5x (C-12.5x), 40x (C-40x), and 
100x (C-100x) magnification. The black arrow indicates the poorly organized 
thrombus present at the interface between the connective tissue in the dome and the 
neck remnant. ................................................................................................................... 82 
 
 xvii 
 
LIST OF TABLES 
 Page 
Table 2.1: SMP foam density and pore diameter (mean ± standard deviation) ............... 23 
Table 2.2: Summary of actuation transitions of SMP foams in solvent (mean ± 
standard deviation) ............................................................................................ 25 
Table 3.1: Aneurysm model and device dimensions and TVO values ............................ 51 
Table 4.1: In vivo Aneurysm Sizes, Packing Density ...................................................... 81 
 
 1 
 
CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW* 
1.1 Intracranial Saccular Aneurysms 
Aneurysmal subarachnoid hemorrhage (aSAH) occurs when an intracranial 
aneurysm ruptures causing bleeding into the subarachnoid space in the brain. Intracranial 
saccular aneurysms occur when the artery wall dilates into a sphere-like sac. As aneurysms 
develop and grow in size, the aneurysm wall thickness decreases, and stiffness increases, 
resulting in an increased risk of rupture from constant blood flow and pressure in the 
aneurysm sac.1 Saccular aneurysms are typically sized by diameter and range broadly in 
size from a few millimeters in diameter to tens of millimeters, though they are reported 
most commonly in the 3-10 mm range.2 Saccular aneurysms typically develop at the apex 
of arterial bifurcations in or near the Circle of Willis at the base of the brain and are 
typically asymptomatic until they rupture, causing aSAH.3 aSAH incidence occurs in 9.7 
– 14.5 out of every 100,000 adults in the United States and is associated with high 
morbidity and mortality rates. aSAH results in the death of at least 25% of patients, and 
approximately 50% of survivors are left with persistent neurological deficit.4 For patients 
                                                 
* Part of this chapter is reprinted with permission from "In vitro and in vivo evaluation of a shape memory 
polymer foam-over-wire embolization device delivered in saccular aneurysm models,” by Anthony J. 
Boyle, Todd L. Landsman, Mark A. Wierzbicki, Landon D. Nash, Wonjun Hwang, Matthew W. Miller, 
Egemen Tuzun, Sayyeda M. Hasan, Duncan J. Maitland, Journal of Biomedical Materials Research Part B 
Applied Biomaterials 2015, 00B:000–000. Copyright (2015) John Wiley and Sons. 
 
Part of this chapter is reprinted with permission from “Solvent stimulated actuation of polyurethane-based 
shape memory polymer foams using dimethyl sulfoxide and ethanol,” by AJ Boyle, AC Weems, SM 
Hasan, LD Nash, MBB Monroe, and DJ Maitland, Smart Materials and Structures 2016, 25 075014. 
Copyright (2016) IOP Publishing. 
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with a neurological deficit, 30% suffer from permanent damage, and 20% require hospice 
care for the remainder of their life.5 Additionally, patients often have more than one 
aneurysm, increasing the risk of subsequent ruptures.6 Therefore, prevention of aneurysmal 
rupture and effective treatment of ruptured aneurysms are essential for reducing morbidity 
and mortality due to aneurysmal subarachnoid hemorrhage. 
1.2 Endovascular Coiling Treatment 
Standard endovascular treatment of intracranial saccular aneurysms involves the 
delivery and implantation of embolization coil devices into the aneurysm with the goal of 
promoting thrombus formation, tissue healing, and neointima growth across the aneurysm 
neck.7 Embolization coils were first introduced to clinical use with the Guglielmi 
detachable coil (GDC®), a bare platinum coil, in 1990 as an alternative to surgical clipping 
methods, which require an invasive craniotomy surgical procedure.8,9 Bare platinum coils 
are typically constructed of platinum-tungsten (Pt/W) alloy wire wound into a primary coil 
and are then shaped in either secondary helical, complex, or spherical geometries.10 During 
endovascular coiling procedures, a microcatheter is introduced into the femoral artery and 
navigated to the aneurysm under x-ray fluoroscopy guidance. An embolization coil device 
is delivered through the microcatheter, deployed into the aneurysm sac, and detached. 
Multiple coil devices are packed into the aneurysm until the sac is visibly occluded, which 
can be seen during angiography or digital subtraction angiography (DSA) as shown in 
Figure 1.1. After implantation, the packed coil mass promotes flow stagnation and 
thrombus formation, which is an essential early step towards cell infiltration, stable healing, 
and neointima formation across the aneurysm neck.7 
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Figure 1.1: Saccular aneurysms post-treatment using GDCs® and bioactive polymer-
coated coils. (A) DSA of loosely packed (empty arrow) bioactive polymer-coated coils 
immediately post-embolization. Contrast is visible at small neck remnant (arrow) and 
throughout aneurysm. (B) DSA of tightly packed GDCs® immediately post-
embolization. (C) Angiography of tightly packed GDCs® immediately post-
embolization with small neck remnant (arrow). (D) Angiography of loosely packed 
(arrow) bioactive polymer-coated coils immediately post-embolization. (Adapted 
from [11] with permission from JNS Publishing Group) 
 
 
 
Endovascular coiling has been shown to be an effective method of treatment for 
intracranial aneurysms, but it remains limited by aneurysm recanalization or recurrence 
despite introduction of new technologies.12,13 In 2005, Molyneux et al. reported that 
endovascular coiling improved patient independent survival at 1 year compared to 
neurosurgical clipping.13 However, endovascular coiling is limited by the risk of aneurysm 
recurrence or recanalization, which involves the return of blood flow into the occluded 
aneurysm and increased risk of rupture and hemorrhage. Diminished packing density, 
defined as the ratio of implanted device volume to aneurysm volume, as well as poor or 
unstable thrombus organization have been associated with increased recurrence, among 
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other mechanisms.14-16 Bare platinum coils have been reported with 30 – 31% packing 
density and unorganized thrombus formation that may not organize within 3 years 
following treatment.17-19 Early studies of recurrence rates following treatment using bare 
platinum coils reported recurrence in 21 – 34% of cases.20,21 Based on these limitations, 
polymer-embedded coils were introduced to improve healing and reduce recanalization 
rates. Biodegradable polymers were used in coil devices, such as Matrix® and Cerecyte®, 
in order to accelerate the inflammation response as a means of stimulating mature tissue 
healing not found with bioinert bare platinum coils.19,22 However, Matrix® coils resulted in 
worse recurrence rates in early studies and no significant difference in recurrence in later 
randomized clinical study compared to bare platinum coils.23-25 Furthermore, Cerecyte® 
coils have resulted in no significant difference in angiographic outcomes compared to bare 
platinum coils in randomized clinical trials.26 HydroCoil® devices were also introduced to 
improve recurrence rates by means of increasing packing density.27 HydroCoils® are coils 
coated with a hydrogel that expands over time during contact with water, displacing blood 
and filling the majority of the aneurysm space.17 However, although they have increased 
packing densities compared to other coil devices, HydroCoils® have not resulted in 
significantly improved long-term clinical outcomes.28 Overall, new coil technologies have 
not improved recurrence rates, and clinical recurrence remains a primary limitation of 
endovascular coiling, occurring in 21% of cases and requiring retreatment in 10% of 
cases.12 
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1.3 Shape Memory Polymer Foams 
Shape memory polymers (SMP) are a unique class of materials capable of 
maintaining a programmed shape and subsequently recovering their original shape in 
response to a stimulus such as heat, light, or moisture.29,30 Thermo-responsive SMPs act 
about a transition temperature (Ttrans) during the shape memory cycle. The SMP is heated 
above Ttrans, deformed into its programmed state into an increased stress configuration, and 
cooled below Ttrans, where low polymer chain mobility holds the SMP in its programmed 
shape. To actuate the polymer and induce shape recovery, the SMP is heated above Ttrans, 
and high polymer chain mobility allows entropic forces in the polymer chains to recover 
to the decreased stress configuration of the original shape of the SMP. Shape recovery 
percentage, defined as the percentage ratio of the recovered strain to the original strain, is 
a key metric of the shape memory cycle and used to evaluate the effectiveness of shape 
recovery. Figure 1.2 illustrates the shape memory cycle for a thermo-responsive SMP.  
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Figure 1.2: The shape memory cycle for a thermo-responsive shape memory polymer. 
(1) Heating above Ttrans. (2) Deforming to programmed geometry while T > Ttrans. (3) 
Cooling below Ttrans while holding programmed shape. (4) Heating above Ttrans to 
recover original shape. 
 
 
 
Polyurethane-based SMP foams have been proposed as an advantageous 
biomaterial for endovascular embolization applications due to their shape recovery 
capability and interconnected, large surface area porosity.1,31,32 Wilson et al. synthesized 
highly crosslinked, amorphous polyurethane SMPs from uniform, aliphatic monomers for 
use in medical devices.29 For endovascular embolization applications, the SMPs were 
fabricated into a porous foam structure in order to achieve large volume recovery and high 
surface area properties.33 These porous SMPs have been reported with tunable physical, 
mechanical, and chemical properties, including but not limited to low bulk densities near 
0.015 g/cm3, sharp glass transition temperatures (Tg) ranging 45 – 75 °C, and consistent 
shape recovery greater than 80%.33,34 Figure 1.3 shows the interconnected porosity of the 
SMP foams. SMP foam composites have also been fabricated using additives such as 
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tungsten and barium sulfate in order to provide x-ray radiopacity and/or tune mechanical 
properties.35-37 Furthermore, biocompatibility of the polyurethane-based SMP foams has 
been evaluated via preliminary benchtop models and porcine animal models. SMP foams 
have been reported with promising cytocompatibility, increased implanted angiographic 
occlusion, integrated connective tissue post-implant, and thicker neointima layer compared 
to bare platinum coils in porcine saccular aneurysm models.1,31,33 The interconnected 
porosity of the SMP foams acts as a scaffold for blood flow and thrombus formation 
throughout the material volume. This morphology contrasts with hydrogel materials used 
in endovascular coils that have pore sizes less than 10 µm and displace blood out of the 
aneurysm volume.1,31 The material properties and characteristics of these polyurethane-
based SMP foams lend them to a novel volume filling and tissue scaffolding solution to 
endovascular embolization procedures. 
 
 
 
 
Figure 1.3: Representative cell structure of foams for all the formulations H80 
through H40. Foams of all formulations show a mixed, closed to open cell structure, 
with thin cell membranes between struts. All scale bars are 500 µm. (Adapted from 
[33] with permission from John Wiley and Sons) 
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1.4 Rationale for Using Organic Solvents for SMP Actuation 
Solvent exposure has been investigated to trigger SMP actuation as an alternative 
to direct heating or stimulation by electricity, light, or magnetic fields.38-40 Solvent 
exposure promotes SMP actuation by swelling into the polymer and plasticizing the 
polymer chains, thereby increasing chain mobility and lowering Ttrans below the 
environment temperature. Figure 1.4 illustrates the use of solvent to stimulate SMP 
actuation by change in Ttrans. Solvent-stimulated actuation avoids limitations of direct 
heating actuation in endovascular applications including poor energy delivery to devices 
due to heat convention of blood flow and risk of heat-induced tissue damage. However, 
previous studies have focused on water as the actuating solvent, which is disadvantageous 
for endovascular applications as devices are exposed to water throughout the entire 
procedure. Polyurethane-based SMP foams have been reported as water-responsive 
materials, exhibiting depressed Tg when exposed to water, which actuates and expands 
compressed devices in physiological conditions.41,42 For water-responsive embolization 
materials such as the hydrogel used in HydroCoil® devices and SMP foam implants, 
endovascular delivery and device repositioning can be significantly impeded or halted due 
to device swelling or expansion. Singhal et al. reported that increasing hydrophobicity of 
polyurethane-based SMP foams resulted in delayed self-actuation due to Tg depression in 
water.41 Although water stimulated actuation design of SMPs provides simpler clinical 
procedures and reduced risk of tissue damage due to a heating device for actuation, the 
procedure is dependent on inconsistent actuation timing. Sufficient working time, the time 
in which the device can be repositioned and retracted back into the microcatheter prior to 
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self-actuation, through SMP foam hydrophobicity has yet to be achieved without severely 
extending the time for self-actuation or completely preventing it at physiological 
conditions. Solvent actuation of SMP materials using organic solvents can provide 
clinician-initiated and controlled actuation without direct heating. Organic solvent–
actuated SMP foams that exhibit significantly delayed or no self-actuation in water provide 
long working times for clinicians while retaining expansion capabilities for improved 
aneurysm filling over platinum coils. 
 
 
 
 
Figure 1.4: Example of SMP transition temperature (Ttrans) change in response to 
contact with water or other solvents. 
 
 
 
However, the injection of organic solvents during endovascular procedures can 
result in pharmacological and toxicological effects on the tissues. Dimethyl sulfoxide 
(DMSO) has been used as a solvent in commercially available liquid embolic materials for 
treatment of intracranial aneurysms and arteriovenous malformations.43-45 Onyx® is a 
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liquid embolic treatment for intracranial aneurysms that implements a polymer dissolved 
in DMSO at 92 – 94% by volume that is carefully injected and subsequently allowed to 
precipitate out of the DMSO solution by blood flow. Onyx® has been successfully used 
clinically since its introduction, motivating interest in DMSO as a solvent for neurovascular 
applications, though research into the toxicological effects of DMSO has raised concerns. 
Liquid intra-arterial infusion of anhydrous DMSO has resulted in full-thickness 
angionecrosis and severe vasospasm.46,47 However, low dose volumes of 0.5 – 0.8 mL with 
slow dose durations over 30 – 120 seconds have been shown to result in significantly less 
angiotoxicity.48,49 In addition, the LD50 for lysis of red blood cells as total volume percent 
in whole blood has been reported for DMSO as 5.1%. In comparison, the use of ethanol 
resulted in a LD50 for red blood cell lysis of 21.2%.
50 Ethanol has also been previously 
studied for liquid embolic applications and use as a parenteral solvent with injections at 
concentrations ranging 10 – 100% depending on application.46,47,51 Intra-arterial infusions 
using ethanol at high concentrations of 70% have produced histological changes and full-
thickness angionecrosis while infusions with concentrations of 10 – 40% resulted in 
necrosis of only the intimal and partially of the medial layer.46,47 Though different solvents 
will result in varying degrees of angiotoxicity, studies with both DMSO and ethanol 
indicated that decreasing the injected solvent concentration resulted in reduced toxicity. 
Therefore, characterizing the SMP foam expansion at varying solvent concentrations is 
imperative to determining the clinical feasibility of solvent actuation. 
The feasibility of using organic solvent–stimulated actuation of SMP foams has yet 
to be fully understood, either in general or for endovascular applications. Therefore, this 
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research aimed to investigate if rapid SMP actuation can be achieved and the necessary 
concentration of solvent in water for clinically relevant expansion times using current 
hydrophobic SMP foams. Solvent-stimulated actuation is a potentially useful alternative 
for actuation of a SMP-based endovascular embolization device in intracranial aneurysm 
treatment, though the method is applicable to several SMP systems for many uses, 
including non-biomedical. Thus, the work discussed here focuses on developing and 
characterizing solvent actuation of SMP foams as a foundation for broad clinical 
application, not only for intracranial aneurysm treatment. 
1.5 Rationale for a SMP Foam-Coated Coil Device Design 
A new endovascular embolization device must address design constraints of the 
complex geometry and physiologic environment of the cerebral vasculature while also 
implementing design inputs proposed to improve clinical outcomes over current 
commercial devices. During the clinical procedure, the device must be deliverable through 
a tortuous pathway with minimal resistance, be able to be retracted back into the 
microcatheter and repositioned multiple times prior to detachment, and be packed into 
aneurysm volume without entering the parent artery. The device must also exhibit 
biocompatibility and be clearly visualized with fluoroscopy. Additionally, a new device 
should provide some approach to improve aneurysm recurrence rates compared to previous 
devices as a means of improving overall clinical outcomes. A device capable of increasing 
aneurysm packing density compared to bare platinum coils and promoting mature 
thrombus organization is hypothesized to decrease recurrence rates and improve long-term 
clinical outcomes.14-16 
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Figure 1.5: H&E Staining (1× and 4× magnification): (A.90) 1× H&E staining of a 
bisected aneurysm after 90 days of implantation, (B.90) 4× H&E staining of the 
central core (square) of the bisected aneurysm after 90 days of implantation, and 
(C.90) 4× H&E staining of foam and parent artery interface (star) after 90 days of 
implantation. All scale bars are 1 mm. (Adapted from [1] with permission from John 
Wiley & Sons) 
 
 
 
A shape memory polymer (SMP) foam-coated coil embolization device can provide 
the volume filling and large surface area properties of SMP foams combined with the 
fluoroscopic contrast and mechanical stability of bare platinum coils. The low densities 
and excellent shape recovery capabilities of SMP foams enable both delivery of a compact 
device through a microcatheter and subsequent expansion to increase bulk volume filling 
per device length compared to current commercial devices.33,34 Furthermore, polyurethane-
based SMP foams can be actuated using exposure water, blood, or saline, and the expansion 
kinetics can be tuned to allow for sufficient working time and can achieve effective volume 
filling.34,41 Though both SMP foams and hydrogels in HydroCoils® exhibit volume filling 
capability, SMP foams exhibit interconnected pores with diameters in the hundreds of 
microns compared to hydrogel pore sizes, which are less than 10 µm.33,52 Therefore, 
compared to HydroCoils®, which displace blood and thrombus from the aneurysm volume, 
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the interconnected porosity of the SMP foams has been shown to act as a scaffold for blood 
flow, thrombus formation, and connective tissue healing throughout the material volume 
in porcine saccular aneurysm models.1,31 Thus, the SMP foam occlusion is achieved 
primarily with thrombus and tissue supported with a small volume of foam scaffold. Figure 
1.5 shows the 90-day histology of the polyurethane-based SMP foam implanted in a 
porcine saccular aneurysm model. SMP foams implanted in porcine saccular aneurysm 
models also resulted in complete endothelialization across the aneurysm ostium with 
minimal inflammation.1,31 However, clinical applications of previously studied devices 
comprised solely of SMP foam are limited due to the need for catheter sizes that are 
incompatible with the cerebral vasculature, insufficient flexibility through tortuous 
neurovascular anatomy, insufficient radiopacity for fluoroscopic imaging, and inconsistent 
device stability in the aneurysm, resulting in SMP foam migration into the parent artery.32 
These limitations can be addressed by combining the novel characteristics of SMP foams 
with a compliant, radiopaque backbone. Platinum-tungsten alloy coils are standard 
materials in endovascular embolization coil devices and are capable of providing both 
excellent compliance and x-ray radiopacity.10 Furthermore, secondary shaping of 
embolization coils has been shown to improve control of deployment and aneurysm 
packing. Nickel-titanium (nitinol) alloys have previously been used as superelastic 
materials for biomedical applications, including neurovascular, and are hypothesized to be 
an effective material for shaping the SMP foam-coated coil into secondary geometries.53,54 
Overall, the SMP foam-coated coil embolization device is hypothesized to improve 
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aneurysm volume occlusion and tissue healing with deliverability and use that is familiar 
to clinicians, resulting in an effective device with a low adoption hurdle for clinicians. 
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CHAPTER II  
SOLVENT STIMULATED ACTUATION OF POLYURETHANE-BASED SHAPE 
MEMORY POLYMER FOAMS USING DIMETHYL SULFOXIDE AND ETHANOL* 
2.1 Introduction 
Shape memory polymers (SMPs) are promising materials due to their ability to 
maintain a temporary shape and subsequently recover their original shape in response to a 
thermal, chemical, or optical stimulus.29,30,55 Thermoresponsive SMPs act about a 
transition temperature (Ttrans), where below Ttrans, low polymer chain mobility holds the 
SMP in its temporary shape and above Ttrans, high polymer chain mobility allows entropic 
forces in the polymer chains to recover the original shape of the SMP. Porous SMPs exhibit 
volume expansion, high surface area-to-volume ratios, permeability, and 
thermomechanical properties that are advantageous for several applications including 
biomedical, aerospace, self-healing materials, and textiles.1,29,33 
Solvent exposure has been investigated to trigger SMP actuation as an alternative 
to direct heating or stimulation by electricity, light, or magnetic fields.38-40 Solvent 
exposure promotes SMP actuation by plasticizing the polymer chains, thereby increasing 
chain mobility and lowering Ttrans below the environment temperature. Previous studies 
have focused on water as the actuating solvent, which is not ideal for several applications 
where water exposure is common to the environment.38,39,56 With water-responsive SMPs, 
                                                 
* Reprinted with permission from “Solvent stimulated actuation of polyurethane-based shape memory 
polymer foams using dimethyl sulfoxide and ethanol,” by AJ Boyle, AC Weems, SM Hasan, LD Nash, 
MBB Monroe, and DJ Maitland, Smart Materials and Structures 2016, 25 075014. Copyright (2016) IOP 
Publishing. 
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water exposure can result in decreased stiffness and stimulate actuation prior to successful 
placement of the material, reducing the effectiveness of porous SMPs for applications such 
as water filtration, textiles, and clinical embolic vascular devices. Porous polyurethane 
SMP foams have been reported as water-responsive materials.41,42 Singhal et al. reported 
that increasing SMP foam hydrophobicity resulted in delayed actuation in aqueous 
environments, but the actuated volume was severely reduced.41 Actuation of non-water-
responsive SMPs with an alternative solvent can provide controlled SMP expansion 
without direct heating and minimize the negative effects of water plasticization on material 
performance and mechanical properties. 
This study aims to investigate the feasibility and sensitivity of solvent-stimulated 
SMP foam actuation with an initial focus of aqueous environments of biomedical 
applications. Two organic solvents were chosen due to an expectation of effective 
polyurethane plasticization and their previous use in biomedical applications: dimethyl 
sulfoxide (DMSO) and ethanol (EtOH). DMSO has been used as a solvent in transdermal 
drug delivery and liquid embolic materials.43,57 EtOH has also been studied for liquid 
embolic applications and for use as a parenteral solvent.46,47,51 However, both DMSO and 
EtOH have been shown to have concentration dependent toxicological effects, indicating 
a need for using diluted solvent solutions for biomedical applications.46,47 SMP foam 
compositions with varying hydrophobicity were investigated for changes in thermo-
mechanical properties and shape recovery when exposed to water and varying 
concentrations of organic solvents. 
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2.2 Materials and Methods 
2.2.1 Shape Memory Polymer Foam Fabrication 
Polyurethane-based shape memory polymer (SMP) foams were synthesized using 
a two-step method with aliphatic isocyanate and hydroxyl monomers as previously 
reported.41 Trimethyl-1,6-hexamethylene diisocyanate, 2,2,4- and 2,4,4- mixture (TMHDI, 
TCI America Inc.), isophorone diisocyanate (IPDI, 98%; Sigma-Aldrich Inc.), N,N,N’,N’-
tetrakis(2-hydroxypropyl)ethylenediamine (HPED, 99%; Sigma-Aldrich Inc.), 
triethanolamine (TEA, 98%; Sigma-Aldrich Inc.), DC 198 (Air Products and Chemicals, 
Inc.), DC 5943 (Air Products and Chemicals, Inc.), T-131 (Air Products and Chemicals, 
Inc.), BL-22 (Air Products and Chemicals, Inc), Enovate 245fa Blowing Agent (Honeywell 
International, Inc.) and deionized (DI) water ( > 17 M Ω cm purity; Millipore water purifier 
system; Millipore Inc.) were used as received. SMP foam compositions were synthesized 
with 0, 10, and 20 mol% of IPDI, with the remaining isocyanate mol% comprised of 
TMHDI, as previously reported by Hasan et al.34 The SMP foam compositions are denoted 
by the respective mol% of IPDI as 0IPDI, 10IPDI, and 20IPDI. 
After the synthesis, SMP foams were processed before being cut into blocks for 
reticulation. As reported by Rodriguez et al, a mechanical wire punch apparatus was used 
for reticulation.58 8 mm diameter, 2-3 cm long cylindrical samples were cut from the foam 
blocks using a biopsy punch. The foam samples were radially compressed to 1 mm 
diameter using a SC250 stent crimper (Machine Solutions, Inc., Flagstaff, AZ), heated to 
100 °C, and subsequently heated to expand to their original shape. SMP foam cylinders 
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were then acid etched, cleaned under sonication, and dried under vacuum, as previously 
reported.34 Foam samples were stored in a sealed container with desiccant. 
2.2.2 SMP Foam Density and Pore Diameter 
SMP foam density was measured for each composition. Bulk foams were cut into 
cubes using a resistive wire cutter from three sections along the foaming axis in accordance 
with ASTM standard D-3574. The length of each cube edge was measured using calipers 
to calculate volume, mass was measured for each foam cube, and density was calculated. 
Pore diameter was measured for each SMP foam composition. Each pore is 
approximately uniform in diameter in the transverse direction and elongated in the axial 
foaming direction. Cleaned SMP foam cylinders were cut into 2-3 mm thick slices along 
the axial and transverse directions. The samples were mounted on a stage and sputter coated 
with gold for 60 seconds at 20 mA using a Cressington Sputter Coater (Ted Pella, Inc., 
Redding, CA). Images were taken using a Joel NeoScope JCM-5000 Scanning Electron 
Microscope (SEM) (Nikon Instruments, Inc., Melville, NY) at 10 kV and 24x 
magnification under high vacuum. ImageJ software (National Institutes of Health, 
Bethesda, MD) was used to measure the maximum diameter of seven pores per sample in 
the axial and transverse directions for two samples of each foam composition. 
2.2.3 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) using a Q-200 DSC (TA Instruments, Inc., 
New Castle, DE) was used to measure the glass transition temperature (Tg) for 
approximately 9 mg +/- 3.0 mg of dry and solvent-swelled samples. The dry sample heating 
profile was ambient to -40.0 °C, isothermal for 2 min, ramp to 120 °C, isothermal for 2 
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min and repeat. The second heating cycle was used to find the half height transition (Tg) 
using TA instrument analysis software. 
Solvent-swelled samples were first submerged in the selected solvent at 37 °C for 
10 min before being mechanically compressed for 2 min to remove residual solvent. The 
samples were then sealed in TZero pans and placed in the DSC. Samples were cooled to -
40 °C from ambient temp, followed by heating to 80 °C (DMSO and Water) or 60 °C 
(EtOH), isothermal for 2 min, cooled back to -40 °C, and then reheated to the same peak 
temperature. For all testing, the heating rate was 10 °C/min. A sample size of 3 was used 
for analysis. 
2.2.4 Dynamic Mechanical Analysis 
Dynamic mechanical analysis (DMA) was performed to determine the mechano-
thermal transitions in various solvents. A TT-DMA (Mettler-Toledo AG, Schwerzenbach, 
Switzerland) was used to perform kinetic and temperature sweeps, applying a static force 
of 0.04 N at a rate of 1 Hz, with a static to dynamic force ratio of 1.5. Foam cylinders (6 
mm diameter and 5 mm length) were heated to 100 °C and axially compressed to 0.8 mm 
before cooling to room temperature under compression. 
Temperature sweeps were used to find the storage modulus (E’) and loss modulus 
(E’’) with the Tg measured as the temperature of the peak ratio of E’/E’’ (tan δ). Solvent 
was cooled to 5 °C or the freezing point of the solvents before being ramped to 
approximately 70 °C at a rate of 1 °C/min. E’ was normalized for each sample to the first 
measurement and plotted vs time. Tg values for each composition were compared to dry Tg 
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values at tan δ reported by Hasan et al.34 Four samples were examined for each composition 
for each solvent. 
Kinetic experiments were used to analyze the actuation of SMP foams submerged 
in solvent over time. Solvent was isothermal at 37 °C for 20 minutes before the sample was 
submerged, and measurements were recorded for 30 min. E’ was normalized for each 
sample to the first measurement and plotted vs time. The n-values for each foam 
composition in water, DMSO, and EtOH were three, seven, and four, respectively, to 
account for variability in kinetic behavior. Kinetic experiments were correlated with 
temperature sweeps to ensure measurement accuracy. 
2.2.5 Swelling Ratio in Solvent Solutions 
Swelling volume ratio was measured over time for each SMP foam composition in 
solvents. SMP foam discs (6 mm diameter and 4-5 mm length) were cut from cleaned and 
dried samples. A 0.09 mm diameter nickel-titanium (nitinol) wire (Nitinol Devices & 
Components, Inc., Fremont, CA) was placed through the disc axis. Sample were then 
imaged, and the sample diameter and length were measured using ImageJ software. 
SMP foam samples were submerged in solvent solutions held at 37 ± 1 °C and 
imaged at fixed time intervals. An aluminum fixture was used to suspend the foam samples 
in the solution and act as a reference scale. Samples were submerged in solution and were 
imaged at 1 min intervals for 5 min of submersion and then at 5 min intervals to 15 min 
total submersion time. ImageJ software was used to measure the diameter and length of 
samples at each time point. Volume was calculated for the samples at each time point. 
Volume ratio % at each time point was calculated using (2.1). Volume ratio of 100% 
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represents the initial volume, while 150% and 200% volume ratio indicate radial swelling 
of 1.14x and 1.26x, respectively. Swelling volume ratio was measured for 3 samples of 
each SMP foam composition in water, DMSO, and EtOH. 
 𝑉𝑜𝑙𝑢𝑚𝑒 𝑅𝑎𝑡𝑖𝑜 % = (
𝑉𝑜𝑙𝑢𝑚𝑒𝑆𝑢𝑏𝑚𝑒𝑟𝑠𝑖𝑜𝑛 𝑇𝑖𝑚𝑒 𝑃𝑜𝑖𝑛𝑡
𝑉𝑜𝑙𝑢𝑚𝑒𝐼𝑛𝑖𝑡𝑖𝑎𝑙
) × 100 (2.1) 
2.2.6 Shape Recovery in Solvent Solutions 
Shape recovery was measured over time for each SMP foam composition in solvent 
solutions with varied concentrations. SMP foam cylinders (2.5 mm diameter and 1 cm 
length) were cut from cleaned and dried samples using a biopsy punch. A 0.09 mm 
diameter nitinol wire was placed through the cylinder axis. The sample diameter and length 
were measured for each SMP foam sample using calipers to calculate pre-compressed 
volume. The SMP foam cylinders were radially compressed to 0.30-0.34 mm diameter 
using a SC250 stent crimper heated to 100 °C. Compressed samples were stored in a sealed 
container with desiccant for minimum of 24 hours before testing.  
SMP foam samples were submerged in solvent solutions held at 37 ± 1 °C and 
imaged at fixed time intervals. An aluminum fixture was used to suspend the foam samples 
in the solution and act as a reference scale. Samples were submerged in solution and were 
imaged at 1 min intervals for 10 min of submersion and then at 5 min intervals to 30 min 
total submersion time. ImageJ software was used to measure the diameter and length of 
actuated sections at each time point. Actuated volume was calculated for the cylindrical 
samples at each time point. Volume recovery at each time point was calculated using (2.1) 
where volume ratio of 100% represents the initial volume. Volume recovery was measured 
for 3 samples of each SMP foam composition in water, DMSO, and EtOH solutions. SMP 
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foam samples were tested in DMSO concentrations of 100, 90, 80, 40, and 0 vol% in water 
and in EtOH concentrations of 100, 80, 50, 20, and 0 vol% in reverse osmosis (RO) water, 
where 0 vol% is the control in 100% RO water. 
2.3 Results and Discussion 
2.3.1 SMP Foam Morphology 
SMP foams were fabricated with similar stable morphology, as shown in Figure 
2.1. Cell membranes are still present with small pinholes created during the reticulation 
process, resulting in a high total surface area with interconnected pores that allow fluid 
flow through the foam volume.58 SMP foams were fabricated with varying isocyanate 
ratios and similar average densities and average pore sizes, as shown in Table 2.1. All SMP 
foam compositions exhibited transverse anisotropy, where pore diameter is greater in the 
axial direction than in the transverse direction. 
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Figure 2.1: SEM images of SMP foams. Foam pores in the transverse direction are 
shown on the top row for (a) 0IPDI, (b) 10IPDI, and (c) 20IPDI compositions. Foam 
pores in the axial direction are shown on the bottom row for (d) 0IPDI, (e) 10IPDI, 
and (f) 20IPDI compositions. 
 
 
 
Table 2.1: SMP foam density and pore diameter (mean ± standard deviation) 
Foam 
ID 
Density (g/cm3) 
(n=2) 
Transverse Pore Diameter 
(µm) (n=14) 
Axial Pore Diameter 
(µm) (n=14) 
0IPDI 0.0138 ± 0.0009 680 ± 130 1070 ± 300 
10IPDI 0.0111 ± 0.0003 600 ± 150 1070 ± 220 
20IPDI 0.0121 ± 0.0002 660 ± 130 1090 ± 210 
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2.3.2 Glass Transition Temperature Shift 
SMP foam glass transition temperatures varied in response to exposure to different 
solvents with greatest decreases in Tg after exposure to EtOH. Average Tg values for each 
SMP foam composition measured using DSC and DMA in the dry condition and after 
submersion in water, DMSO, and EtOH are shown in Table 2. 20IPDI was the only 
composition to exhibit a water-submerged Tg above body temperature (37 °C), indicating 
minimal actuation at body temperature. Increasing IPDI content resulted in an increase in 
Tg in all cases when measured by DMA, due to decreased bond rotation. However, 10IPDI 
foams demonstrated lower Tg than both 0IPDI and 20IPDI foams with solvent exposure 
when measured by DSC. This suggests increased plasticization of 10IPDI foams, 
particularly in DMSO, though there is insufficient data to conclude any statistical 
significance. From these results, it’s suggested that increasing IPDI content is effective at 
muting or preventing SMP actuation in water while allowing for actuation in DMSO and 
EtOH.  
 25 
 
Table 2.2: Summary of actuation transitions of SMP foams in solvent (mean ± standard deviation) 
Foam 
ID 
Dry Water DMSO EtOH 
Tg (DSC) 
(°C) (n=3) 
Tg (tan δmax) 
(°C) [34] 
Tg (DSC) 
(°C) (n=3) 
Tg (tan δmax) 
(°C) (n=3) 
Tg (DSC) 
(°C) (n=3) 
Tg (tan δmax) 
(°C) (n=7) 
Tg (DSC) 
(°C) (n=3) 
Tg (tan δmax) 
(°C) (n=4) 
0IPDI 66 ± 1 105 ± 2 35 ± 2 46 ± 1 8 ± 3 28 ± 6 -6 ± 4 18 ± 1 
10IPDI 74 ± 1 118 ± 2 33 ± 1 51 ± 1 -1 ± 3 33 ± 1 -9 ± 5 18 ± 3 
20IPDI 79 ± 2 131 ± 1 44 ± 4 61 ± 1 12 ± 3 41 ± 3 2 ± 4 22 ± 8 
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2.3.3 Actuation Kinetics and Profiles 
Kinetic experiments exhibited distinct actuation transitions in the relaxation 
behavior of the SMP foams submerged in DMSO and EtOH at 37 °C. Relaxation times 
were longest in water and shortest in EtOH as shown in Figure 2.2, where the normalized 
storage modulus is shown for 20IPDI in each solvent. For water and DMSO, no relaxation 
behavior was seen within 30 minutes, as demonstrated by the lack of a decreasing 
inflection in the in normalized modulus. However, DMSO does begin to show reduction 
in modulus within the examined time, contrasted to the modulus increase exhibited in 
water. In contrast, SMP foams in EtOH demonstrated rapid relaxation within 1 minute. 
The increased rate of actuation for all foams in EtOH compared to in DMSO is supported 
by Table 1, where average Tg values are 8 – 19 °C less in EtOH compared to DMSO 
values. Figure 2.3 illustrates the actuation behavior of all foam compositions submerged 
in EtOH. 0IPDI and 10IPDI foams actuated at a slightly increased rate in EtOH compared 
to 20IPDI, though high variance was observed and relaxation time differed by less than 1 
minute. 
 
 
 
 27 
 
 
Figure 2.2: Actuation of 20IPDI foam immersed in varying solvents at 37 °C, 
demonstrated with measurements of storage modulus over time normalized to the 
initial modulus value. 
 
 
 
 
Figure 2.3: Actuation of varying SMP foam compositions immersed in 37 °C EtOH, 
demonstrated with measurements of storage modulus over time normalized to the 
initial modulus value. 
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Swelling tests showed significant increase in SMP foam volume after submersion 
in DMSO and EtOH and minimal to no volume increase in water. All SMP foam 
compositions exhibited noticeable swelling within 5 min of exposure to DMSO and within 
2 min of exposure to EtOH as shown in Figure 2.4. Volume ratio of 100% represents the 
initial volume, while greater than 100% volume recovery represents solvent swelling into 
the polymer, where 150% and 200% volume recovery indicate radial swelling of 1.14x 
and 1.26x, respectively. 10IPDI foam experienced swelling to greater than 175% volume 
in both solvents. However, decreased IPDI resulted in greater swelling in DMSO while 
increased IPDI resulted in greater swelling in EtOH. SMP foams experienced less swelling 
in water, exhibiting volume ratio % values of 104 ± 1.7% for 0IPDI, 109 ± 8.3% for 
10IPDI, and 108 ± 1.4% for 20IPDI after 15 min exposed to water.  
 
 
 
 
Figure 2.4: Swelling volume ratio in 37 °C solvent solutions. Volume ratio is shown 
over time of submersion in (a) DMSO and (b) EtOH. 
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Volume recovery testing demonstrated that submersion in water resulted in 
minimal foam actuation for all compositions while DMSO and EtOH both stimulated 
actuation with a solvent concentration dependence, as shown in Figures 2.5 and 2.6. Figure 
2.7 shows selected images of the foam actuation in 100% and 20% EtOH solutions. All 
SMP foam compositions actuated to less than 15% volume recovery in water after 30 min, 
with 20IPDI actuating the least amongst compositions to less than 3% volume recovery. 
All SMP foam compositions exhibited greater than 100% volume recovery in 100% and 
90% DMSO solutions after 20 min submersion. However, minimal actuation was 
observed in DMSO concentrations less than 90%, with only 10IPDI in 80% DMSO 
actuating greater than 30% volume recovery. All SMP foam compositions exhibited 
greater than 100% volume recovery in 100% and 80% EtOH solutions after 3 min 
submersion. 0IPDI and 20IPDI actuated to greater than 100% volume recovery in 50% 
EtOH within 3 min, and 0IPDI and 10IPDI actuated to greater than 100% volume recovery 
in 20% EtOH within 25 min. Volume recovery testing demonstrates a plasticization 
sensitivity to EtOH that is not shown with DMSO, where the EtOH is sufficiently more 
effective as a plasticizer over water, even in dilute concentrations. 
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Figure 2.5: Volume recovery in 37 °C DMSO solutions. Volume recovery is shown 
over time of submersion in DMSO solutions of varying concentrations for SMP foam 
compositions of (a) 0IPDI, (b) 10IPDI, and (c) 20IPDI, where 0% DMSO is 100% 
RO water. Note the break in the Time axis between 5 and 10 min. 
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Figure 2.6: Volume recovery in 37 °C EtOH solutions. Volume recovery is shown 
over time of submersion in EtOH solutions of varying concentrations for SMP foam 
compositions of (a) 0IPDI, (b) 10IPDI, and (c) 20IPDI, where 0% EtOH is 100% RO 
water. Note the break in the Time axis between 5 and 10 min. 
 
 
 32 
 
 
Figure 2.7: Images of 20IPDI actuation in 37 °C EtOH solutions. (a), (b), (c), and (d) 
show 20IPDI actuation in 100% EtOH at 0, 1, 2, and 5 min, respectively. (e), (f), (g) 
and (h) show 20IPDI actuation in 20% EtOH at 0, 5, 10, and 20 min, respectively. 
 
 
 
Both swelling and shape memory effects are critical factors in the SMP foam 
volume recovery shown in this study. Previous studies on solvent-stimulated actuation 
have reported that the swelling of solvent into the polymer matrix changes the internal 
energy and decreases the relaxation time.56,59 As shown in Figures 2.4, 2.5, and 2.6, all 
foam compositions exhibited swelling to greater than their original volumes during 
submersion in 100% solutions of both DMSO and EtOH. The rates of volume ratio 
increase during the swelling experiment and the volume recovery experiments are very 
similar for all foam compositions. However, while EtOH exposure resulted in an expected 
decrease in relaxation time and Tg (tan δmax) values below 37 °C for all foam compositions, 
DMSO exposure did not cause the same result. Rather, as shown for 20IPDI in Figures 
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2.2, 2.4, and 2.5, DMSO exposure resulted in polymer swelling but minimal to no 
relaxation in DMA kinetic experiments. This suggests differing mechanisms through 
which DMSO and EtOH influence volume recovery. During swelling, solvent penetrates 
into the polymer matrix and separates the polymer chains, increasing overall volume and 
enabling viscous migration between polymer network and solvent.59 During shape 
recovery, heating the polymer above Ttrans increases chain mobility, allowing entropic 
forces to orient polymer chains from the organized state of the temporary shape to the 
disorganized state of the original shape.30 This study suggests that DMSO exposure 
primarily causes volume change due to solvent swelling separating polymer chains, 
increasing volume, but stimulation of the conformational change and polymer chain 
orientation during shape recovery is less of a factor. Thus, both swelling and shape 
recovery influence volume recovery, but swelling may dominate the volume change that 
occurs without chain relaxation expected. However, EtOH exposure was observed to 
cause both volume change from swelling as well as relaxation during shape recovery. 
Thus, rapid volume recovery occurs as a result of both swelling and shape recovery as 
indicated by the expected chain relaxation. 
We hypothesize that the mechanism and effectiveness of solvent-stimulated 
actuation is heavily dependent on the relative molecular interactions of the solvent and 
polymer backbone. In these studies, EtOH proved to be a much more effective plasticizer 
of the polyurethane-based SMP foams than DMSO and water. This is likely caused by two 
primary factors: (1) the solvent’s ability to penetrate the SMP and plasticize the polymer 
backbone and (2) the availability of isocyanate species to plasticization and mobility. Lu 
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et al. demonstrated that submersion in EtOH decreased the Tg of polyurethanes as a 
function of time due to hydrogen bonding interactions between the solvent and the 
urethane linkages.56 However, previous studies of solvent-stimulated actuation of 
polyurethanes reported opposite results to this study; namely, decreased shape recovery 
was observed with EtOH compared to water, which was attributed to stronger hydrogen 
bonding interactions between urethane linkages and water relative to those with EtOH.38,56 
These differing results reinforce that interactions between the chosen solvent and specific 
polymer chemistry are critical to the shape recovery effect. The SMP foam chemical 
compositions used in these studies were designed for increased hydrophobicity and 
decreased water plasticization, as reported by Hasan et al.34 Methyl groups in the 
isocyanate monomers in combination with the ring structure of IPDI hinder water 
penetration into the polymer backbone, reducing available isocyanate linkages for water 
plasticization.34 We hypothesize that the presence of both polar and non-polar regions in 
the EtOH molecule allow for drastically increased interactions with this polymer backbone 
compared to water and DMSO. Specifically, the OH functionality in the EtOH molecule 
will readily interact with urethane linkages while the C-C tail will interact with the non-
polar regions of the isocyanates. Further investigation is required to fully characterize and 
understand the mechanisms underlying the solvent stimulated SMP foam actuation 
observed in this study. 
2.4 Conclusion 
Solvent-stimulated volume recovery of hydrophobic polyurethane-based SMP 
foams using DMSO and EtOH was shown. Dramatic decreases in Tg were observed with 
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exposure to water, DMSO, and EtOH. EtOH was shown to decrease SMP foam relaxation 
times to less than 1 min in DMA kinetic experiments. Furthermore, rapid shape recovery 
and volume swelling was observed for SMP foams in high concentrations of both DMSO 
and EtOH, as well as in decreased concentrations of EtOH. This study demonstrates 
effective control of SMP foam volume recovery using both DMSO and EtOH, including 
in aqueous environments, and that pairing of polymer composition and solvent selection 
is critical to the effectiveness of this actuation technique. Future work should investigate 
other solvents, as use of EtOH and DMSO are not ideal solvents in many applications, 
including biomedical applications due to moderate to severe toxicological effects.46,47 
However, this work serves as a proof of concept of SMP foam actuation control using 
non-water solvents and provides insight into mechanisms that can be investigated for 
future material and device design work. Overall, this work demonstrates great potential 
for use of solvents as an alternative actuation stimulant for polyurethane-based SMP foams 
and may improve feasibility of using SMP materials in a variety of applications. 
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CHAPTER III  
IN VITRO AND IN VIVO EVALUATION OF A SHAPE MEMORY POLYMER 
FOAM-OVER-WIRE EMBOLIZATION DEVICE DELIVERED IN SACCULAR 
ANEURYSM MODELS* 
3.1 Introduction 
3.1.1 Endovascular Treatment of Intracranial Saccular Aneurysms 
Intracranial saccular aneurysms typically develop at the apex of subarachnoid 
arterial bifurcations at the base of the brain.3 Subarachnoid hemorrhage, primarily caused 
by ruptured intracranial aneurysms, affects approximately 1 in 10,000 Americans each 
year and is fatal in 35% to 50% of all patients.3 
Standard endovascular treatment using bare metal coils involves delivering several 
platinum wire coils through a microcatheter into an aneurysm to occlude the aneurysm 
volume.8,9 The treatment goal is for the packed coils to provide sufficient flow stasis to 
result in embolization of the aneurysm sac and neointima growth across the aneurysm 
neck. However, implanted bare platinum coils are prone to compaction, result in low 
volume occlusion ranging from 23-37%, and exhibit a recanalization rate of 21-34% with 
13% requiring retreatment.20,21,60-63 Minimal tissue response to the bioinert platinum coils 
stunts tissue healing, resulting in unorganized thrombus formation within the aneurysm 
sac that may not organize within 3 years following treatment.19 Several devices, including 
                                                 
* Reprinted with permission from “In vitro and in vivo evaluation of a shape memory polymer foam-over-
wire embolization device delivered in saccular aneurysm models,” by Anthony J. Boyle, Todd L. 
Landsman, Mark A. Wierzbicki, Landon D. Nash, Wonjun Hwang, Matthew W. Miller, Egemen Tuzun, 
Sayyeda M. Hasan, Duncan J. Maitland, Journal of Biomedical Materials Research Part B Applied 
Biomaterials 2015, 00B:000–000. Copyright (2015) John Wiley and Sons. 
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polymer embedded coils, have been investigated in order to improve upon bare platinum 
coiling outcomes. Bioactive and biodegradable polymer coated coils increase tissue 
response, but are susceptible to recanalization as the polymer is absorbed.23 HydroCoils® 
(Microvention Inc., Tustin, CA) are platinum coils coated with a bioinert poly(acrylamide-
co-acrylic acid) hydrogel with pores less than 10 µm in diameter.52 The hydrogel swells 
in water, displacing blood as it fills the aneurysm volume, resulting in volume occlusion 
ranging 45-85%.17,18,27 Although major recurrence has been reported to be lower when 
using HydroCoils®, the effect on long-term clinical outcomes is unclear.28 
3.1.2 Proposed Shape Memory Polymer Foam Treatment 
Shape memory polymers (SMP) exhibit the ability to maintain a temporary shape 
and subsequently recover their original shape in response to a thermal, chemical, or optical 
stimulus.30 SMPs fabricated into a foam geometry are advantageous for endovascular 
embolization due to their large surface area to volume ratios that enable large volume 
transitions required for catheter delivery and subsequent aneurysm occlusion.33 Biostable 
polyurethane SMP foams have been reported with 700-1000 µm pores, biocompatibility, 
and tunable thermal and mechanical properties for improved actuation control.1,33 Unlike 
hydrogels, the large pores of SMP foam provide channels for blood flow and a scaffold 
for interconnected thrombus formation, cell infiltration, and tissue healing throughout the 
foam volume.1,33 
Previous studies investigating saccular aneurysm occlusion using SMP foam 
documented excellent aneurysm occlusion, mild inflammatory response, and mature tissue 
healing.1 However, these devices were designed for catheters too large for conventional 
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neurovascular applications, functionally different than standard coils, and not visible 
under fluoroscopy.  
Therefore, a new device design was developed to provide a low adoption hurdle 
for clinicians familiar with standard coils and enable delivery through traditional 
microcatheters using fluoroscopy. The device design employs a SMP foam that is 
delivered to the aneurysm over a radiopaque nickel-titanium (nitinol) and platinum wire 
backbone, mechanically detached, and then actuated either passively using physiological 
conditions or using a laser heated injection. Devices were fabricated, tested in simulated 
actuation methods, and delivered to in vitro and in vivo saccular aneurysm models. 
Delivery and detachment efficacy, laser heating efficacy, aneurysm volume occlusion, and 
acute clotting were measured and evaluated during the studies. 
3.2 Materials and Methods 
3.2.1 Embolization Device Design and Fabrication 
The embolization device system consisted of an SMP foam-over-wire (FOW) 
implant device and a cable tube delivery and detachment device with an optional laser 
heated saline injection for SMP foam expansion as shown in Figure 3.1. 
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Figure 3.1: Schematic diagrams of the SMP foam-over-wire (top panel), the delivery 
and detachment device (middle panel), and the laser heating mechanism (bottom 
panel). 
 
 
 
3.2.1.1 Shape Memory Polymer Foam-over-Wire Implant 
The implant device consists of SMP foam secured around a platinum wound nitinol 
backbone wire (Figure 3.1, top panel). N,N,N′,N′-Tetrakis(2-
hydroxypropyl)ethylenediamine (HPED, 99%), triethanolamine (TEA, 98%), trimethyl-
1,6-hexamethylene diisocyanate, 2,2,4- and 2,4,4- mixture (TMHDI), and deionized (DI) 
water (> 17 MΩ cm purity) were used as received to synthesize SMP foams using protocol 
reported previously.41 Under sonication, 8 mm SMP foam cylinders were chemically 
etched in 0.1 M hydrochloric acid, cleaned using isopropyl alcohol and detergent, and then 
rinsed with reverse osmosis (RO) water. Cleaned foam cylinders were dried overnight in 
an oven at 50 °C under vacuum. 
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The platinum-nitinol wire backbone was annealed over a mandrel in a furnace to 
set a helical shape, quenched in water, and cleaned using isopropyl alcohol. SMP foam 
cylinders were cut from the cleaned and dried cylinders using a 2.5 mm diameter biopsy 
punch blade adhered to the end of a 2.97 mm ID stainless steel tube and the wire backbone 
was threaded axially through the SMP foam (Figure 3.2A). Devices were fabricated with 
both 2 cm and 4 cm total lengths of SMP foam. The implant devices were held taught and 
the SMP foam was radially compressed (Figure 3.2B) using a heated SC250 Stent Crimper 
(Machine Solution Inc.®, Flagstaff, AZ). Medical grade UV-cure epoxy was used to secure 
the compressed SMP foam at each end of the device. 
 
 
 
 
Figure 3.2: FOW embolization device. A) The threaded device prior to radial 
compression and attachment to the delivery and detachment device. Scale is mm. B) 
The assembled embolization device with compressed FOW device attached to the 
delivery and detachment device. 
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3.2.1.2 Delivery and Detachment Device 
The braided coil assembly (Figure 3.1, middle panel) consisted of a 0.31 mm OD 
stainless steel ACTONETM cable tube (Asahi Intecc Co., Aichi, Japan) reinforced with a 
0.46 mm OD stainless steel ACTONETM cable tube for distal flexibility and reinforced 
proximal pushability. A nitinol retention wire was passed through the entire length of the 
braided coil assembly. A laser welding system was used to secure a platinum marker band 
4 mm from the distal tip of the braided coil assembly. A ball tip was created on each end 
of the implant using the laser welder and the ball tip was press-fit into the distal tip of the 
delivery system on top of the retaining wire, causing the braided coil to distend and apply 
a spring force on the ball tip. A second platinum marker band was laser welded at the 
distal tip of the delivery system to constrain the implant ball tip. The assembled devices 
were individually sealed in a sterilized pouch with desiccant and, for the in vivo studies, 
sterilized by ethylene oxide and allowed to degas for 24 hours. 
3.2.1.3 Laser Heater Device and Injection 
Fiber optic cables were fabricated using 200/220/239 µm core/cladding/buffer 
optical fiber and connectorized with 230 µm ST epoxy fiber connectors. Reinforced 
furcation and polytetrafluoroethylene tubing segments were placed over the proximal 30 
cm of the fiber. Gold marker bands were epoxied to the optical fiber at the distal tip and 2 
cm proximal to the distal tip using medical grade thermal cure epoxy. Two platinum wires 
were laser welded to opposite sides of the marker bands and wound around the fiber. The 
injected solution consisted of phosphate buffered saline doped with indocyanine green 
(ICG) at a concentration of 375 µM. The concentration was chosen to achieve a 
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penetration depth of approximately 300 µm by interpolating data collected by Landsman 
et al.64 A full schematic of the laser heated injection is shown in the bottom panel of Figure 
3.1. 
3.2.2 In vitro Device Studies 
3.2.2.1 SMP Foam Actuation 
SMP foam actuation was characterized using simulated passive and active 
actuation methods. FOW devices were submerged in 37 °C RO water to simulate passive 
actuation and imaged at 2 min interval to 20 min and 5 min interval to 60 min total 
submersed time. To simulate active actuation, devices were submerged in 37 °C RO water 
for 5 min, then submerged in 50 °C RO water and imaged at 1 min interval to 15 min total 
submersed time. Imaging software was used to measure the foam diameter at 5 points 
along the length of each sample at each time point. 
3.2.2.2 Aneurysm Model Fabrication and Flow System 
An aneurysm model consisting of a 10 mm diameter sphere embedded in the side 
of a 5 mm diameter cylinder was designed in CAD software, printed using a fused 
deposition modeling system, and smoothed using sandpaper. Sylgard 184 
polydimethylsiloxane (PDMS, Dow Corning Corp., Midland, MI) was cast and cured 
around the model, and the printed model was dissolved using a heated base bath. 
During testing, the PDMS aneurysm model was inserted in a flow loop as shown 
in Figure 3.3. Heated RO water was siphoned into a bath with the aneurysm model to 
maintain isothermal conditions at 37 °C. One peristaltic pump was used to maintain the 
water level above the submerged aneurysm model. A second peristaltic pump and pulse 
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dampener supplied steady flow through the parent artery of the PDMS aneurysm model at 
approximately 240 mL/min to match the Reynold’s Number of human common carotid 
artery peak blood flow rates reported by Holdsworth et al.65 A needle thermocouple was 
placed through a small port at the aneurysm dome to monitor temperature during setup 
and removed prior to device delivery. 
 
 
 
 
Figure 3.3: In vitro flow system schematic. The solid line indicates the simulated 
artery flow through the PDMS aneurysm model. The dashed line indicates the 
isothermal bath flow. 
 
 
 
3.2.2.3 Embolization Device Delivery and Evaluation 
Multiple FOW embolization devices were delivered via microcatheter into the 
aneurysm model. A 2.8/2.3 F proximal/distal microcatheter with a 0.53 mm lumen was 
navigated to the aneurysm using a guidewire. For each device, a hemostasis valve was 
used to secure a stainless steel hypotube introducer and the devices were advanced through 
the microcatheter to the aneurysm. Each device was positioned into the aneurysm such 
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that the entire implant device was contained inside the aneurysm and the proximal 
platinum band at the distal tip of the delivery and detachment device was out of the 
microcatheter. The retaining wire on the delivery and detachment device was removed 
proximally and the cable tube was retracted into the microcatheter for complete release of 
the implant. The SMP foam passively actuated in the 37 °C water after implantation. 
Multiple devices were inserted into the aneurysm until the aneurysm was considered 
sufficiently occluded. Occlusion was indicated by qualitative visualization of extended 
dwell time or prevention of dye infiltrating the aneurysm. Theoretical volume occlusion 
(TVO) was calculated using Equation 3.1,  
 𝑇𝑉𝑂 =
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where Vf is expanded foam volume, Va is the aneurysm volume, Df is the expanded foam 
diameter, Lf is the total foam length, and Da is the aneurysm diameter. The TVO 
calculation assumes the aneurysm is spherical and the SMP foam is a uniform cylinder of 
1.25 mm diameter. 
3.2.2.4 Laser Heater Characterization 
Laser heater characterization was performed by recording the temperature of the 
aneurysm dome during heated injection in an in vitro flow loop similar the one shown in 
Figure 3.3. A microcatheter was passed through a hemostasis valve to the aneurysm dome. 
The optical fiber was inserted through a Y-adapter hemostasis valve and the tip was 
positioned approximately 2 cm proximal to the distal tip of the catheter. The ICG solution 
was injected using a syringe pump through the Y-adapter on the microcatheter. Systemic 
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flow was discontinued and the ICG injection was initiated at a flow rate of 1.5 mL/min. 
An 808 nm continuous wave diode laser was activated to emit radiation at approximately 
1.9-2 W. The temperature in the dome of the aneurysm was measured every ten seconds 
for two minutes. Three devices were used and three injections were characterized for each 
device. 
3.2.3 In vivo Device Study 
3.2.3.1 Porcine Sidewall Saccular Aneurysm Model Creation 
Animal studies were conducted in accordance with policies set by the Texas A&M 
University Institutional Animal Care and Use Committee, and met all federal requirements 
as defined in the Animal Welfare Act, the Public Health Service Policy, and the Humane 
Care and Use of Laboratory Animals. Additionally, studies observed NIH guidelines (or 
for non-U.S. residents similar national regulations) for the care and use of laboratory 
animals (NIH Publication #85-23 Rev. 1985). 
Animal studies were performed in the catheterization laboratory at the Texas A&M 
Institute for Preclinical Studies. Fluoroscopic visualization was achieved using the Allura 
Xper FD20 system (Koninklijke Philips N.V., Eindhoven, The Netherlands). A saccular 
sidewall vein pouch aneurysm model created in a 3-4 month old, 30-40 kg Yorkshire swine 
using a previously described model.66 Study subjects were premedicated with Telazol 5 
mg/kg and 0.01 mg/kg buprenorphine administered intramuscularly. Following 
endotracheal intubation, study subjects were mechanically ventilated and maintained on 
isoflurane. Using sterile technique, a 10 cm incision was made in the ventral cervical 
midline and using a combination of sharp and blunt dissection the external jugular vein 
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and carotid arteries were isolated. A 4 cm long segment of the external jugular vein was 
isolated, excised, and divided transversely to create two 2 cm open-ended pouches. The 
common carotid arteries were cleaned of adventitia, and vascular clamps placed at each 
end of the target area on the artery. A 3-4 mm arteriotomy was created and an end-to-side 
anastomosis of the venous pouch to the carotid artery performed using 7-0 polypropylene 
sutures. A 6-9 mm diameter aneurysm was created on each common carotid artery of two 
animals for a total of four aneurysms. After hemostasis was confirmed, the subcutaneous 
tissues were loosely closed. 
3.2.3.2 Embolization Device Delivery and Angiographic Evaluation 
Each aneurysm was accessed via endovascular technique for device delivery and 
implantation. A 6 F intravascular sheath was inserted percutaneously into the femoral 
artery with ultrasound guidance and a 5 F guide catheter was inserted through the 
introducer. Using fluoroscopic guidance, the guide catheter was advanced over a 
guidewire to the proximal right or left carotid artery proximal to the aneurysm. Digital 
subtraction angiography with 3-D reconstruction angiography was performed to fully 
characterize each aneurysm. A 2.8/2.3 F proximal/distal microcatheter with 0.53 mm 
lumen was navigated to the aneurysm using a guidewire. Multiple FOW embolization 
devices were delivered through microcatheters and deployed in each aneurysm under 
fluoroscopic guidance. Devices were delivered and detached using the same methods used 
during in vitro studies. After implantation, the SMP foam passively expanded in the 
physiological conditions. Additional devices were inserted into the aneurysm until the 
aneurysm was considered sufficiently occluded. Implant time was measured per aneurysm 
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as the time between entry of the first device into the microcatheter and detachment of the 
final device. Adequacy of occlusion was determined qualitatively by visualization of 
extended dwell time or prevention of dye infiltrating the aneurysm. TVO was calculated 
using Equation 1, where Da was the aneurysm diameter averaged from four measurements 
taken from angiographic images obtained using various angles, with the same assumptions 
as conducted for in vitro studies. 
3.2.3.3 Laser Heated Injection 
The laser heated injection was used in one aneurysm after implantation with FOW 
devices to accelerate and increase expansion of the SMP foam. The laser heating device 
was positioned using the same methods used during in vitro studies. A second 6 F 
introducer was inserted into the femoral artery on the opposite side of the previous 
introducer. A 5 F balloon catheter was inserted through the second introducer and 
positioned proximal to the aneurysm site adjacent to the guide catheter. The balloon 
catheter was inflated to prevent blood flow to the aneurysm and ICG-doped saline was 
injected at 1.5 mL/min through the microcatheter. The same laser used for in vitro studies 
was activated for 2 min during injection. After injection, the balloon catheter was deflated 
and angiography was performed to confirm aneurysm integrity and assess any change in 
aneurysm occlusion. 
3.2.3.4 Ex vivo Evaluation 
After implantation and angiographic imaging of both aneurysms in each animal, 
the animal was sacrificed and the aneurysms explanted and rinsed in saline. The parent 
artery was divided axially and the aneurysm neck was exposed and imaged. The aneurysm 
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wall was opened and the implanted devices were imaged within the aneurysm sac and 
after removal from the aneurysm to evaluate implant device stability, aneurysm occlusion, 
and clotting. 
3.3 Results 
3.3.1 In vitro Device Studies 
3.3.1.1 SMP Foam Actuation 
As shown in Figure 3.4, SMP foam submerged in 37 °C RO water actuated to an 
average diameter less than 0.53 mm after 5 min, 1.26 mm after 30 min, and 1.44 mm after 
60 min. After 5 minutes of submersion in 37 °C RO water, SMP foam submerged in 50 
°C RO water actuated to an average diameter of 1.02 mm within 1 min and 1.65 mm after 
10. Three samples were tested per actuation method. 
 
 
 
 
Figure 3.4: SMP foam expansion using simulated passive and active actuation 
methods. 
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3.3.1.2 Embolization Device Delivery 
The spherical aneurysm model was fabricated with a dome diameter of 9.79 ± 0.12 
mm and a neck diameter ranging 2.09-6.81 mm. Embolization device delivery into the 
aneurysm model is shown in Figure 3.5. Four FOW devices 4 cm in length were delivered 
to the aneurysm model. Two of four implant devices were detached without complication, 
whereas two devices detached in the microcatheter during repositioning and were 
successfully deployed using a guidewire. All four devices were implanted into the 
aneurysm model without migration into the parent vessel. TVO was calculated to be 40%. 
 
 
 
 
Figure 3.5: FOW device in vitro delivery. A) Aneurysm model prior to device 
delivery. B-E) Delivery of four devices into the aneurysm model. F) Aneurysm model 
is well occluded. 
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3.3.1.3 Laser Heater Characterization 
The conducted in vitro tests showed that three of the tested devices increased the 
aneurysm dome temperature to at least 49 °C after 1-1.5 minutes of injection. 
 
 
 
 
Figure 3.6: Heating profile of three different laser heating devices each tested three 
times. 
 
 
 
3.3.2 In vivo Device Study 
3.3.2.1 Embolization Device Delivery and Angiographic Evaluation 
After aneurysm formation, three of four aneurysms exhibited good stability via 
angiography, while one aneurysm showed hemorrhage at the anastomosis site. All four 
aneurysms were successfully treated with FOW embolization devices with an average 
implant time of 65.0 ± 16.4 min. Figure 3.7 summarizes angiographic evaluation of each 
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aneurysm before and after treatment. All treated aneurysms exhibited significant 
occlusion, particularly at the dome apex, with reduced contrast infiltration into the 
aneurysm. Hemorrhage at the anastomosis site shown in panel D.1 is no longer seen after 
treatment as shown in panel D.2. The minimal TVO calculated for the four aneurysms was 
72% (Table 3.1). 
 
 
 
Table 3.1: Aneurysm model and device dimensions and TVO values 
Aneurysm 
Label 
Aneurysm 
Diameter 
(mm) 
Neck 
Diameter 
(mm) 
No. 
Devices 
Total 
Device 
Length 
(cm) 
Theoretical 
Volume 
Occlusion 
A 8.66 ± 1.45 4.42 6 20.0 72% 
B 7.45 ± 1.11 4.63 4 16.1 91% 
C 7.78 ± 1.91 4.42 6 14.9 74% 
D 5.74 ± 0.77 3.40 3 11.4 141% 
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Figure 3.7: FOW device treatment of porcine sidewall aneurysms labeled A, B, C, 
and D. Top Row: Digital subtraction angiography prior to device implantation. 
Bottom Row: Digital subtraction angiography after implantation of FOW devices. 
 
 
 
Embolization devices were delivered and implanted in the aneurysms with 
minimal complications. All device components were clearly identified under fluoroscopy. 
19 of 26 (73%) FOW devices inserted into the microcatheter were successfully implanted 
in aneurysms, two devices could not be packed into aneurysms that had already occluded, 
and five devices could not be advanced due to excessive device expansion within the 
catheter. Delivery and detachment of devices was successfully performed in 24 of 26 
(92%) attempts with both complications being detachment of the implant during 
repositioning. One detached device was delivered to the aneurysm using a guidewire and 
the other was partially packed in the aneurysm and subsequently removed using an 
endovascular snare system. As shown in Figure 3.8, the laser heated injection was 
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conducted without complication and no acute adverse reactions were detected. Minimal 
reduction in contrast infiltration was observed following the laser heated injection. 
 
 
 
 
Figure 3.8: Laser heated injection for increased SMP foam expansion. A) 
Fluoroscopic image prior to balloon inflation and ICG-doped saline injection. Digital 
subtraction angiography of treated aneurysm prior to (B) and after (C) laser heated 
injection. 
 
 
 
3.3.2.2 Ex vivo Evaluation 
The explanted aneurysms showed no device perforation through the aneurysm wall 
and excellent thrombus formation throughout the implanted FOW devices. Figure 3.9 
shows an explanted aneurysm and the aneurysm content of implanted devices and 
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thrombus. All aneurysms were explanted within 3 hours after final device implantation in 
each aneurysm. 
 
 
 
 
Figure 3.9: Explanted porcine sidewall aneurysm model. A) Digital subtraction 
angiography of the aneurysm prior to treatment. B) Digital subtraction angiography 
of the aneurysm after implantation of four FOW devices. C) Explanted aneurysm 
including parent vessel. D) Visualization of the explanted aneurysm neck. E) Partial 
removal of the explanted aneurysm wall. F) Thrombus with the implanted devices is 
stable after removal from the aneurysm. Scale is mm. 
 
 
 
3.4 Discussion 
The primary goal of these studies was to evaluate the efficacy of FOW 
embolization devices for endovascular treatment of saccular aneurysms. The devices were 
tested using in vitro and in vivo saccular aneurysm models to measure and evaluate 
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delivery and detachment efficacy, laser heating efficacy, aneurysm volume occlusion, and 
acute clotting. 
Passive SMP foam actuation indicated a 5 min working time, during which time 
the foam is smaller than the delivery microcatheter ID (0.53 mm). This is equal to 
published repositioning times of the HydroCoils®.27 However, the foam diameters of 1.26 
mm at 30 min passive actuation and 1.02 mm at 1 min active actuation are both greater 
than reported expanded diameter of HydroCoils® of 0.69 mm, indicating higher occlusion 
per device length of the FOW compared to HydroCoils®.27 
The embolization device delivery in vitro demonstrated excellent positioning of 
multiple devices in the saccular aneurysm model with no device protrusion or migration 
into the parent vessel (Figure 3.5). The device detachment success rate of 50% revealed a 
need for increased grip strength and consistency in fabrication, both of which were 
implemented for devices fabricated for the in vivo study. Theoretical volume occlusion 
(TVO) of the in vitro study was lower than expected due to limited total device length of 
16 cm relative to the large aneurysm diameter, but still resulted in greater than reported 
volume occlusion values for bare platinum coil treatments.60,61 
All three laser heating devices increased the temperature (Figure 3.6) in the 
aneurysm dome during in vitro studies to a temperature 10 °C greater than the published 
SMP foam transition temperature for successful SMP foam actuation.41 Heating profile 
variation could be due to device imperfections or variation in the connector alignment and 
fiber tip location in the catheter. 
 56 
 
Post treatment angiography during the in vivo study shown in Figure 3.7 exhibited 
complete elimination of flow into the aneurysm dome apex and substantial reduction of 
flow near the aneurysm neck in all 4 aneurysm models. FOW devices treated all porcine 
aneurysms with an average total device length of 15.6 cm, which is less than the average 
values reported when using bare platinum coils (52-53 cm) or HydroCoils® (31-38 cm) 
in similar sized aneurysms. Additionally, FOW device treatments resulted in TVO ranging 
72-141%, which is equal to or greater than those reported by bare platinum coils (29-31%) 
or HydroCoils® (76-86%) in similar sized aneurysms.17,18 However, the aneurysm D 
value (Table 1) may be falsely high due to angiography measurements underestimating 
the actual diameter of the aneurysm possibly due to incomplete contrast filling due to the 
anastomosis hemorrhage of aneurysm D (Figure 3.7 D.1) before treatment. The porous 
structure and low radiographic contrast of the SMP foam enables contrast agent to 
infiltrate the foam and be visualized under fluoroscopy. Therefore, the absence of contrast 
agent flow into the aneurysm indicates complete thrombus formation within the implanted 
SMP foam. This is drastically different compared to treatments with bare platinum coils 
that saturate the aneurysm space with radiographic contrast, preventing visualization of 
any infiltrating contrast agent, and with HydroCoils® that displace blood from the 
aneurysm with hydrogel.17 In those cases, occlusion by thrombus formation cannot be 
reliably assessed in vivo. Thrombus formation within the porcine aneurysm models was 
confirmed by evaluation of the explanted aneurysms as shown in Figure 3.9. All aneurysm 
contents exhibited stable thrombus formation throughout the implant device mass. The 
formation of stable thrombus is an early and critical step in the inflammation response that 
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has been shown to promote fibrous connective tissue formation within implanted SMP 
foams. The pore interconnectivity of the SMP foam enables connective tissue integration 
throughout the device volume within 30 days.1 This differs from occlusion with platinum 
coils that may not result in organized thrombus within 3 years or with HydroCoils® that 
show tissue deposition within 2-6 weeks around the devices, but little to no integration 
within the hydrogel due to the pore size.17,19 The thrombus formation throughout the 
explanted aneurysm mass also suggests that flow penetrating into two of the four treated 
aneurysms is an artifact of the 2D imaging overlaying flow around the outside of the ball 
of implanted contents. 
Embolization devices were implanted with stable positioning of multiple devices 
in each saccular aneurysm model. Implant times for FOW devices were longer than 
reported average procedure times for platinum coils (27 min) and HydroCoils® (28 min) 
due to device complications.17 Implant devices had a moderate success rate with 
complications of increased delivery friction due to foam expansion in the microcatheter 
indicating a need for increased foam hydrophobicity to delay passive expansion.41 
Detachment devices were able to deliver, reposition, and retract almost all devices without 
complication. The two detachment device complications were the direct result of either a 
fully packed aneurysm preventing device delivery or undesired SMP foam expansion and 
can be addressed without a detachment design change. The laser heating injection resulted 
in minimal decrease of contrast infiltration in the treated aneurysm, indicating either 
complete passive expansion of SMP foams or that the temperature increase was not 
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sufficient to increase SMP foam expansion. However, no negative acute effects were 
observed as a result of the laser heating. 
3.5 Conclusions 
In conclusion, the FOW embolization device design combines the filling and 
surface area advantages of SMP foam with fluoroscopic contrast and mechanical stability 
of metal coils, providing a low adoption hurdle for clinicians experienced with coil 
devices. Furthermore, the in vitro and in vivo studies show great promise for the efficacy 
of the FOW embolization device for endovascular treatment of intracranial saccular 
aneurysms. 
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CHAPTER IV  
IN VITRO AND IN VIVO PERFORMANCE OF A SHAPE MEMORY POLYMER 
FOAM-COATED COIL EMBOLIZATION DEVICE 
4.1 Introduction 
Aneurysmal subarachnoid hemorrhage (aSAH), bleeding into the subarachnoid 
space in the brain due to intracranial aneurysm rupture, is marked by significant morbidity 
and mortality rates. Incidence of aSAH occurs in 9.7 – 14.5 out of every 100,000 adults in 
the United States where at least 25% of patients die and approximately 50% of survivors 
are left with persistent neurological deficit.4 Standard endovascular treatment of 
intracranial saccular aneurysms involves the delivery and implantation of embolization 
coil devices into the aneurysm to promote thrombus formation, tissue healing, and 
neointimal growth across the aneurysm neck.7 However, aneurysm recurrence after 
endovascular coiling occurs in 20.8% of cases, requiring retreatment in 10.3% of cases.12 
Diminished packing density, which is the ratio of implanted device volume to aneurysm 
volume, as well as poor or unstable thrombus organization have been associated with 
increased recurrence, among other mechanisms.14-16 Polymer-embedded coils, including 
poly(glycolic acid) and hydrogel-coated coils, were introduced to increase packing density 
or improve thrombus organization but have not resulted in significantly improved long-
term clinical outcomes.26,28 Therefore, the need still exists for an embolization device 
capable of increasing packing density and improving thrombus organization. 
Shape memory polymer (SMP) foams have been proposed as an advantageous 
biomaterial for endovascular embolization applications due to their shape recovery 
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capability and interconnected, large surface area porosity.1,31,67 Thermo-responsive SMP 
foams are capable of being programmed to hold a temporary shape until stimulated by 
heat, at which time they recover their original shape.29,33 SMP foams have been reported 
with increased angiographic occlusion, more advanced healing marked by mature 
connective tissue, and a thicker neointima layer compared to bare metal coils in porcine 
saccular aneurysm models.1,31 Though both SMP foams and hydrogels exhibit volume-
filling capability, SMP foams exhibit interconnected pores with diameters in the hundreds 
of microns, compared to hydrogel pore sizes less than 10 µm in diameter.33,52 This 
interconnected porosity of the SMP foams acts as a scaffold for blood flow, thrombus 
formation, and tissue healing throughout the material volume.1,31 
A prototype embolization device was previously designed using radially 
expanding SMP foam over a nickel-titanium (nitinol) and platinum wire backbone and 
demonstrated to have stable angiographic occlusion and clot formation in a porcine 
saccular aneurysm model.67 However, the device exhibited some limitations including 
restricted working time, i.e. time allowed to deliver and reposition the device, and 
excessive stiffness that increased packing difficulty. To address these limitations, a SMP 
foam-coated coil (FCC) embolization device was designed utilizing SMP foam over a 
platinum alloy coil with nitinol core wire. The FCC device is designed to interface with a 
delivery wire and electrolytic detachment system similar to systems previously used with 
commercial devices. This study evaluated selected performance and biocompatibility 
characteristics of the implant device, including ease of delivery and working time through 
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physiologically simulated tortuous flow models and cytocompatibility, to assess 
feasibility of the device for clinical treatment of intracranial saccular aneurysms. 
4.2 Materials and Methods 
4.2.1 Device Fabrication 
The foam-coated coil (FCC) device is composed of shape memory polymer (SMP) 
foam placed over a platinum-tungsten coil with nickel-titanium (nitinol) core wire. 
Trimethyl-1,6-hexamethylene diisocyanate, 2,2,4- and 2,4,4- mixture (TMHDI, TCI 
America Co., Portland, OR), N,N,N′,N′-Tetrakis(2-hydroxypropyl)ethylenediamine 
(HPED, 99%, Sigma-Aldrich Co., St. Louis, MO), triethanolamine (TEA, 98%, Sigma-
Aldrich Co., St. Louis, MO), and deionized (DI) water (> 17 MΩ cm purity) were used as 
received to synthesize SMP foam as previously reported by Hasan et al.34 Helical shaped 
coil assemblies composed of nickel-titanium wire inserted through the lumen of a 
platinum-tungsten coil were used as received (Heraeus, Hanau, Germany). For each 
device, SMP foam was cut into cylinders using a 1 mm diameter biopsy punch, and the 
coil assembly was threaded through the foam cylinder axis. A single leading coil loop was 
left uncoated by SMP foam at the distal end. The SMP foam cylinder was saturated with 
a 4 vol% solution of TMHDI, HPED, and TEA in tetrahydrofuran (THF, anhydrous, EMD 
Millipore Co., Darmstadt, Germany) and then cured by temperature ramp up to 120 °C at 
20 °C/hr and held at 120 °C for 2 hr. The resulting SMP coating adheres the foam to the 
coil. Under sonication, the devices were cleaned using reverse osmosis (RO) water and 
isopropyl alcohol (IPA) and then dried at 100 °C for 12 hr under vacuum. SMP foam was 
heated to approximately 100 °C and radially compressed around the coil using a SC250 
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stent crimper (Machine Solutions Inc., Flagstaff, AZ) to 0.016 ± 0.001 inches (0.41 ± 0.03 
mm) in diameter. FCC devices were fabricated with a helical diameter of 6 mm and 
straight length of 10 cm (6x10), a helical diameter of 4 mm and straight length of 6 cm 
(4x6), or a straight length of 20 cm (0x20). The devices were placed into a 0.022 inch 
(0.56 mm) inner diameter (ID) polytetrafluoroethylene (PTFE) tubing for storage and use 
as an introducer sheath. 
For tests using microcatheters, devices were attached to delivery wires. Delivery 
wires were removed from various sized GDC® embolization coils (Stryker Co., 
Kalamazoo, MI) and attached to the proximal (clinician side) end of the FCC using 203A-
CTH-F UV-cure epoxy (Dymax Co., Torrington, CT). Figure 4.1 shows a foam-coated 
coil device before and after radial compression. 
 
 
 
 
Figure 4.1: SMP foam-coated coil embolization device. (A) FCC device, 6x10 size, 
prior to radial compression. (B) FCC device, 6x10 size, after radial compression. (C) 
FCC device, 6x10 size, after expansion in 37 °C water for 30 min. 
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4.2.2 Shape Recovery 
SMP foam expansion rate was characterized in an aqueous environment. FCC 
devices, 6x10 size, were straightened and submerged in 37 ± 0.2 °C RO water. Images 
were taken at 1 min intervals to 10 min total time submerged and at 5 min intervals to 30 
min total time submerged. Foam diameter was measured at 5 different locations along 
each sample length for each time point using ImageJ software (NIH, Bethesda, MD). 
4.2.3 Microcatheter Tip Deflection 
Change in microcatheter tip angle during device deployment was measured to 
assess device stiffness. A 0.022 inch (0.56 mm) ID Trevo Pro 18 microcatheter (Stryker 
Co., Kalamazoo, MI) was steam shaped into a 110° angle with a 1 mm radius of curvature 
and secured in place. The starting tip angle was measured prior to each sample test from 
the image using ImageJ software. 
Tip deflection was measured for FCC devices, 6x10 size, with delivery wire and 
GDC-18 2D devices (Stryker Co., Kalamazoo, MI) as controls. Samples were introduced 
into the microcatheter hub and advanced until the device distal tip was 2 cm proximal to 
the microcatheter tip. The delivery wire was clamped in an Insight 30 material tester 
system (MTS) (MTS Systems Co., Eden Prairie, MN) proximal to the microcatheter hub. 
The MTS advanced the device 0.5 cm through the microcatheter, and an image was taken. 
This was repeated until 5 cm was deployed out of the microcatheter. The tip angle was 
measured in each test image using ImageJ software and subtracted from the starting tip 
angle in order to calculate the tip deflection angle. 
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4.2.4 Ease of Delivery and Working Time 
Ease of delivery and working time were evaluated on FCC devices through a 
tortuous path with physiologically simulating flow. Tubing with 2.38 mm ID was secured 
into a tortuous path with radii of curvature and curve angles based on a model reported by 
Sugiu et al. and as shown in Figure 4.2.68 DI water was heated and pumped through the 
tubing at average flow rate of 44 ± 2 mL/min. Flow rate was calculated by matching the 
in vitro system Reynold’s number to in vivo measurements of the middle cerebral artery 
reported by Reymond et al.69 Inlet and outlet temperatures were maintained at 37 ± 1 °C. 
A 0.022 inch (0.56 mm) ID Trevo Pro 18 microcatheter was passed through the tortuous 
path until the microcatheter tip was past the tortuous path and held in 6.35 mm ID tubing. 
DI water was flushed through the microcatheter at 0.4 mL/min using a syringe pump. 
 
 
 
 
Figure 4.2: Tortuous path for ease of delivery and working time testing. The distal 
tip of the FCC implant is placed at (A) the entry of the tortuous path to start ease of 
delivery testing. The device is advanced until the junction to the delivery wire 
reaches (B) to end ease of delivery testing. 
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Ease of delivery was assessed for FCC devices, 6x10 size, attached to delivery 
wires with GDC-18 2D devices as controls. Devices were introduced into the 
microcatheter, and a timer was started. Devices were then advanced until the distal tip of 
the device was flush with the start of the tortuous path. The delivery wire was secured 
vertically and clamped 30 cm proximal to the microcatheter hub using a MTS with 50N 
load cell. Delivery force, the force experienced by the clinician during a procedure, was 
measured as the device was advanced 29 cm at 14.5 cm/min until the device tip was flush 
with the microcatheter. 
Working time was then assessed for FCC devices following ease of delivery 
testing. The delivery wire was re-clamped in the MTS 6 cm proximal to the microcatheter 
hub. The delivery force was then measured as the device was deployed 5 cm out and 
retracted 5 cm at 10 cm/min to simulate repeated device repositioning. The deploy/retract 
cycle was repeated until an end point was observed: a successful retraction after the total 
submersion time exceeded 10 min, or mechanical damage was observed during a 
retraction cycle. A submersion time threshold of 10 min was chosen based on SMP foam 
shape recovery testing. Once an end point was reached, the total submersion time was 
recorded as the working time. 
4.2.5 Cytocompatibility 
A neutral red uptake test was performed on FCC devices to assess 
cytocompatibility. Dulbecco’s modified eagle medium (DMEM; VWR, Radnor, PA), 
penicillin/streptomycin (P/S, 1%; VWR, Radnor, PA), newborn calf serum (NBCS, 10%; 
Sigma-Aldrich Co., St. Louis, MO), and fungizone (0.1%, VWR, Radnor, PA) were used 
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as received to create cell culture media. Two FCC devices, 6x10 size, were submerged in 
10 mL of cell culture media held at 37 °C for 72 hours while under agitation. 
3T3 fibroblasts (ATCC, Manassas, VA) were seeded in tissue culture plates at a 
concentration of 5,000 cells per well and placed in a humidified incubator at 37 °C with 
5% carbon dioxide (CO2) for 24 hours. An Eclipse TE 2000-S inverted microscope (Nikon 
Instruments Inc., Tokyo, Japan) was used to observe cell morphology and confirm even 
cell distribution. Cell culture media was aspirated and cells were incubated with 100%, 
50%, 25%, and 10% extract to assess cytocompatibility. Diluted extracts were prepared 
by adding fresh cell culture media of the appropriate volume. A cytotoxic control (50% 
IPA), a cytocompatible control (cell culture media that underwent the extraction process 
with no device), and an untreated control (fresh cell culture media) were included to ensure 
the validity of the assay. Cells were incubated at 37 °C with 5% CO2 for 48 hours. 
Extract media was removed, and a neutral red uptake assay (TOX4, Sigma-Aldrich 
Co., St. Louis, MO) was added to assess cell viability. Neutral red is actively transported 
across the cell membrane where it accumulates within lysosomes. Cells were incubated 
with neutral red for 2.5 hours and then fixed using a solution of 0.1% calcium chloride 
(CaCl2, Sigma-Aldrich Co., St. Louis, MO) in 0.5% formaldehyde (0.5%; Sigma-Aldrich 
Co., St. Louis, MO). The neutral red was solubilized using a solution of 1% acetic acid 
(Sigma-Aldrich Co., St. Louis, MO) in 50% ethanol (Sigma-Aldrich Co., St. Louis, MO). 
The optical density at 540 nm (OD540) was measured using an Infinite
® M200 Pro plate 
reader (Tecan Group Ltd., Männedorf, Switzerland) to quantify the remaining neutral red 
in each well. Cell viability, expressed as a percentage, was calculated using Equation 1, 
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where test is the FCC device extract group, blank is a well with no cells, and the control 
is used as a standard for 100% cell viability. 
 
 
 
 controlnegativeOD
testOD
testviabilityCell
540
540
 (4.1) 
4.2.6 In vitro Aneurysm Model Deployment 
Coiling stability and packing density were assessed in an in vitro saccular 
aneurysm model. A saccular aneurysm with a 6.4 mm major diameter, 4.2 mm minor 
diameter, and 3.9 mm neck diameter on a 3.1 mm diameter parent vessel was designed in 
SolidWorks software (Dassault Systems, Waltham, MA). The aneurysm and parent vessel 
model was printed using a Fortus 360mc 3D printer (Stratasys Ltd., Eden Prairie, MN). 
The model was suspended in acetone vapor to smooth the outer surface and then dried 
under vacuum. Sylgard 184 polydimethylsiloxane (PDMS) (Dow Corning Corp., 
Midland, MI) was cast, cured around the model, and the model was dissolved using a 
heated base bath. The PDMS aneurysm phantom was placed in a flow system, and 1x 
phosphate buffered saline (PBS) was heated and pumped through the tubing at average 
flow rate of 66 ± 2 mL/min. Flow rate was calculated by matching the in vitro system 
Reynold’s number to in vivo measurements of the middle cerebral artery reported by 
Reymond et al.69 Inlet and outlet temperature were maintained at 37 ± 0.5 °C. A 0.022 
inch (0.56 mm) ID microcatheter was positioned with the tip in the aneurysm phantom. 
FCC devices, 4x6 size, attached to delivery wires were introduced into the 
microcatheter and advanced to the aneurysm phantom. A device was deployed into the 
aneurysm until the detachment zone on the delivery wire was out of the microcatheter. 
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The device was detached by passing a 1.0 mA current through the delivery wire and by 
placing an uncoated needle in the flow system to electrolytically dissolve the detachment 
zone on the delivery wire. This was repeated until a subsequent device could not be easily 
packed into the aneurysm phantom. Bulk packing density, which assumes the foam is a 
solid volume, was calculated using Equation 2. Material packing density, which accounts 
for the porosity of the foam, was calculated using Equation 3. Porosity of SMP foam used 
in these devices was calculated to be 95% using the method published by Hasan et al.35 
 
volumeAneurysm
volumebulkFCC
densitypackingBulk 
 (4.2) 
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  (4.3) 
4.2.7 In vivo Aneurysm Model Deployment 
Elastase-induced saccular aneurysms were created in New Zealand white rabbits 
at the origin of the right common carotid artery as reported by Altes et al.70 Two weeks 
post aneurysm creation a non-invasive, intra-arterial digital subtraction angiography 
(DSA) imaging checkup was performed. 
At three weeks following aneurysm creation, embolization coil devices were 
implanted within the aneurysm. A guide catheter was inserted through introducer sheath 
and positioned in the brachiocephalic artery proximal to the aneurysm. A Rebar-18 
microcatheter (ev3 Neurovascular, Irvine, CA) with a 0.021 inch (0.53 mm) ID was 
positioned through the guide catheter with the microcatheter tip in the aneurysm. An intra-
arterial DSA was performed, fluoroscopic images were taken, and the aneurysm and neck 
diameters were measured. A coil device was introduced into the microcatheter and 
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deployed under fluoroscopic guidance into the aneurysm until the detachment section was 
visibly out of the microcatheter. The coil device was then detached in the aneurysm. This 
was repeated until the aneurysm was sufficiently occluded by angiographic observation, 
or subsequent devices could not be safely implanted into the aneurysm as directed by the 
clinician. Following treatment, a DSA was performed. Axium coils, 6x20 size, (ev3 
Neurovascular, Irvine, CA) and FCC devices, 2x2 and 4x6 sizes, were used in this study. 
Device performance was observed and evaluated throughout the procedure. Furthermore, 
bulk packing density was calculated using Equation 4.2, which assumes the coil devices 
are solid volumes. Following aneurysm treatment, the sheath entry site is closed, and the 
animal is returned to the recovery cage. 
4.2.8 Explant and Histological Analysis 
Histological analysis was performed on the aneurysm sites. Following a 30-day 
wait period after treatment, a DSA was performed. After angiography, the animal was 
euthanized using a lethal injection of pentobarbital. The aortic arch and proximal great 
vessels are exposed and dissected free from surrounding tissues. The aneurysm and parent 
artery were removed. The specimen was immediately rinsed with normal saline and placed 
in 10% neutral buffered formalin. The aneurysms were embedded, sectioned, and surface 
stained using hematoxylin and eosin (H&E) as previously reported by Ding et al.17 The 
following features were studied: (1) fibrinous or cellular tissue across the neck, (2) 
microcompaction at the aneurysm-parent artery interface, (3) tissue reaction around the 
implant material, and (4) inflammation. 
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4.3 Results and Discussion 
4.3.1 Shape Recovery 
SMP foam expansion of foam-coated coil devices in RO water at 37 °C is shown 
in Figure 3. Three samples were tested. FCC devices expanded to an average diameter of 
0.5 mm at 5 min, 0.56 mm at 10 min, and 0.68 mm at 30 min submersion time. The device 
expansion is slow in physiological conditions, suggesting an estimated working time of 
10 min. This estimated working time was confirmed during working time testing discussed 
in section 3.3. Furthermore, the expansion at 30 min is approximately equivalent to 
expanded diameters of hydrogel-coated coils published in 2007, though current 
commercial hydrogel coated devices exhibit decreased expanded diameter in 
comparison.52 
 
 
 
 
Figure 4.3: SMP foam shape recovery. Average diameter and standard deviation of 
three FCC devices are shown over time submerged in 37 °C RO water. The dashed 
line represents the inner diameter (ID) of the microcatheter used in subsequent tests. 
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4.3.2 Microcatheter Tip Deflection 
Tip deflection angle during device deployment is shown in Figure 4 for FCC and 
GDC-18 2D control devices. Five FCC samples and three control samples were tested. 
Average peak deflection angle was 3.976 ± 1.58 ° for FCC devices and -2.92 ± 1.51 deg 
for control devices. Both FCC and control devices exhibited negative tip deflection during 
deployment of the leading coil loop. However, as the foam-coated section of the FCC 
passed through the microcatheter bend, the microcatheter tip angle was increased. This 
contrasts with the control devices, which exhibited minimal change in deflection angle 
during deployment of the device. This test indicates that FCC devices exhibit greater 
stiffness than control devices. However, the absolute peak angle of tip deflection of FCC 
devices is similar to control devices, and the effect of the observed deflection angles on 
clinical procedures requires additional study. Future studies should investigate alternative 
stiffness evaluation methods in order to provide comprehensive assessment of FCC device 
deployment. 
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Figure 4.4: Microcatheter tip deflection during device deployment. Average angle of 
deflection and standard deviation are shown for five FCC and three control devices. 
Length deployed indicates the length of device deployed out of the microcatheter tip. 
 
 
 
4.3.3 Ease of Delivery and Working Time 
Delivery forces during advancement through the tortuous pathway are shown in 
Figure 5 for FCC and GDC-18 2D control devices. Five FCC samples and three control 
samples were tested. The average peak force was 0.14 ± 0.01 N for FCC devices and 0.18 
± 0.02 N for control devices. One FCC sample delivery force data was omitted for the 
initial 2.3 cm of travel distance shown in Figure 6 due to excessive resistance exerted on 
the delivery wire by the hemostasis valve at the microcatheter hub. The valve was opened 
to decrease resistance at 2.3 cm travel distance, and the remaining dataset includes the 
complete FCC sample data. No other samples experienced this test error. FCC devices 
exhibited similar delivery forces as the control devices throughout the travel distance, 
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indicating that the FCC implant provides no additional resistance to delivery through 
tortuous pathways compared to current commercial devices. 
 
 
 
 
Figure 4.5: Ease of delivery through tortuous pathway. Average delivery force is 
shown over the travel distance through the tortuous pathway for five FCC devices 
and three control devices. Standard deviations are shown every 0.9 cm of travel 
distance. A moving average over 2 mm travel distance was applied to the delivery 
force data. 
 
 
 
Delivery forces during repositioning cycles are shown in Figure 4.5. Five FCC 
devices were tested. Average absolute peak force was 0.62 ± 0.24 N during deployment 
and 0.42 ± 0.06 N during retraction. All devices exhibited a working time equal to or 
greater than 10 min whereby all devices could be fully retracted into the microcatheter 
after 10 min of total submersion time in simulated physiological conditions. However, 
samples 3 – 5 exhibited delivery wire buckling during deployment. During delivery wire 
buckling, the FCC implants were not deployed out of the microcatheter and thus were not 
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retracted into the microcatheter during the following cycle. Instead, the buckled delivery 
wire exerted a negative, or compressive, force on the load cell as indicated by the black 
arrows in Figure 4.6. At the start of the subsequent deploy cycle, the delivery wire was 
guided by hand into the microcatheter to prevent buckling. All devices successfully 
retracted into the microcatheter during the final test cycle. 
 
 
 
 
Figure 4.6: Delivery forces during working time assessment. Delivery force for five 
FCC devices is shown over the submersion time as samples were deployed out and 
retracted into the microcatheter. Positive force indicates retraction, and negative 
force indicates deployment. The black arrows indicate that buckling of the delivery 
wire proximal to the microcatheter hub had occurred on the previous deploy cycle, 
causing no implant motion and no subsequent retraction on the indicated cycle. A 
moving average over 0.5 s submersion time was applied to the delivery force data. 
 
 
 
FCC devices provide repositioning with minimal to moderate resistance up to and 
greater than 10 min following introduction of the device into the microcatheter. This 
working time is greater than the published repositioning time of 5 min for hydrogel coated 
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coils.27 Working time is a critical metric for clinical adoption as coils must be able to be 
easily repositioned inside the aneurysm for effective packing and reduced risk of device 
migration into the parent vessel. Though all FCC devices in this study exhibited working 
time equal to or greater than 10 min, future studies should investigate greater time points 
with greater sample sizes to ensure consistent and reliable repositioning during clinically 
relevant working times. 
4.3.4 Cytocompatibility 
Cell viability of 3T3 fibroblasts exposed to FCC device extracts is shown in Figure 
4.7. Average values are shown for each of 100%, 50%, 25%, and 10% extract 
concentrations, with six wells per concentration. No morphological changes were 
observed after cell exposure to device extracts. Average cell viability from device extracts 
ranged 105-114%. All samples resulting in cell viability greater than 100% show excellent 
cytocompatibility of FCC devices and provide promise for overall device 
biocompatibility. Future studies should assess biocompatibility through other standard test 
methods as cytocompatibility is limited to assessment of extracts and not implanted 
devices. 
 
 
 
 76 
 
 
Figure 4.7: Cytocompatibility of FCC devices by neutral red uptake assay. Cell 
viability of 3T3 fibroblasts is shown for FCC devices compared to blank and control 
groups. Average viability of six wells is shown with standard deviation for each 
extract concentration. 
 
 
 
4.3.5 In vitro Aneurysm Model Deployment 
Device deployment into the in vitro aneurysm model is shown in Figure 10. Three 
FCC devices, 4x6 size, were implanted into the aneurysm model. Packing of the third FCC 
device was hindered by excessive resistance to buckling. As the aneurysm was packed, 
less volume was available for coiling to occur, and microcatheter kick-back, i.e. pushing 
back of the microcatheter tip out of the aneurysm, occurred repeatedly. Although all three 
devices were successfully implanted into the aneurysm, future studies should investigate 
buckling force of FCC devices in various sized aneurysm models. 
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Figure 4.8: FCC device deployment into in vitro aneurysm model. (A) Aneurysm 
model prior to device deployment. Air bubbles in the system are visible. (B) First 
FCC device deployment. (C) Second FCC device deployment. (D) Third FCC device 
deployment. (E) Packed aneurysm model 30 min after implant of the third device. 
(F) Reverse side of packed aneurysm model 30 min after implant of third device. 
 
 
 
Bulk packing density was calculated to be 37% with no foam expansion and 92% 
with foam expansion. These packing densities are similar to published average values for 
bare platinum coils (30-31%) and hydrogel-coated coils (76-85%).17,18 As increased 
packing density has been associated with stable long-term occlusion, the large bulk 
packing densities achieved with expanded FCC devices suggest that stable long-term 
occlusion in vivo can be achieved.14,15 However, though FCC device bulk packing density 
is very similar to current commercial devices, the actual implanted material volume is 
much less due to the SMP foam porosity. Material packing density was calculated to be 
11% for FCC devices in the in vitro aneurysm model. This large bulk packing density with 
small material packing density is potentially advantageous as the FCC device provides 
scaffolding throughout the majority of the aneurysm space while allowing the majority of 
the volume to be filled by stable thrombus formation and healed tissue. This may improve 
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upon previous devices as bare platinum coils provide less bulk occlusion, and hydrogel-
coated coils displace blood instead of providing porous scaffolding throughout the 
aneurysm volume. In vivo studies should be conducted to investigate the effect of high 
porosity occlusion from FCC devices on aneurysm treatment. 
4.3.6 In vivo Aneurysm Model Treatment 
FCC devices were successfully delivered and implanted into three aneurysms with 
minimal procedural complications. Once the devices were clear of the delivery sheath, 
they delivered smoothly through the microcatheter with minimal resistance. However, 
during deployment and packing, devices exhibited excessive stiffness and caused 
significant microcatheter kick-back, similar to that observed during in vitro aneurysm 
deployment. As shown in Figure 4.9, the device stiffness resulted in visibly sparse packing 
of the FCC devices into the aneurysm and one case of a single coil loop implanted in the 
parent artery. Aneurysm volume, devices implanted, and bulk packing density are listed 
for each aneurysm in Table 4.1. Average bulk packing density was calculated to be 51.6 
± 3.1%, which is greater than published values for bare platinum coils (30-31%).17,18 This 
suggests that positioning the implants localized to the aneurysm dome may have resulted 
in increased occlusion density within the bulk implanted mass compared to bare platinum 
coils. This increased packing density is hypothesized to increase thrombus stability and 
healing within the bulk implanted mass. Thus, if packing and positioning of FCC devices 
can be improved and leave less untreated aneurysm volume, the resulting bulk implanted 
mass may provide improved healing and long-term stability compare to bare platinum 
coils. FCC devices exhibited less visibility under fluoroscopy compared to the Axium coil 
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used, though this is expected as the OD of the platinum coil used in FCC devices is less 
than the OD of the Axium coil. FCC devices were not able to be tracked in the guide 
catheter and were difficult to track while in the microcatheter. These limitations of 
excessive stiffness and insufficient radiopacity must be addressed prior to translation to 
clinical use. However, all devices were successfully detached and post-treatment 
angiography showed minimal contrast infiltration into the aneurysm dome with contrast 
infiltration into the neck of all aneurysms. The minimal contrast infiltration into the 
sparsely packed aneurysm domes suggests thrombus formation within the porous SMP 
foam during the procedure. 
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Figure 4.9: Digital subtraction angiography (DSA) images of the aneurysms prior to 
and after treatment. The top row shows DSA images of aneurysm A prior to 
treatment (A), after treatment (A.0), and 30 days after treatment (A.30), where white 
arrows indicate the edge of contrast infiltration through the neck and into the dome 
of the aneurysm. The middle row shows DSA images of aneurysm B prior to 
treatment (B), after treatment (B.0), and 30 days after treatment (B.30), where white 
arrows indicate the edge of contrast infiltration through the neck and into the dome 
of the aneurysm and black arrows indicate a section of an implanted device left in 
the parent artery after premature detachment occurred. The bottom row shows DSA 
images of aneurysm C prior to treatment (C), after treatment (C.0), and 30 days after 
treatment (C.30), where white arrows indicate the edge of contrast infiltration 
through the neck and into the dome of the aneurysm. 
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Table 4.1: In vivo Aneurysm Sizes, Packing Density 
Aneurysm 
ID 
Aneurysm volume 
(mm3) 
Implanted 
Devices 
Bulk Packing 
Density 
A 87 1 Axium6x20 
1 FCC4x6 
2 FCC2x2 
53% 
B 76 1 FCC4x6 
4 FCC2x2 
55% 
C 90 2 FCC4x6 
2 FCC2x2 
48% 
 
 
 
4.3.7 Histological Analysis 
Explanted aneurysms displayed significant neck remnants with loose connective 
tissue filling the majority of aneurysms in and around the implanted devices. Gross 
evaluation of each aneurysm showed neck remnants open to the parent artery as also 
visible in 30 day DSA images. A thin membrane coats the surface of the implant materials, 
indicating partial to nearly complete endothelial layer development. Figure 4.10 shows 
sectioned slide images of each aneurysm evaluated during histological analysis. 
Connective tissue with dense, diffuse inflammatory tissue is visible within and around the 
eosinophilic SMP foam material. Multinucleated giant cells were primarily surrounding 
the SMP foam material with some lymphocytes and macrophages distributed throughout 
the tissue. A nearly complete endothelial layer with thin and thick neointima lined the 
interface between the connective tissue and neck remnant the aneurysms. Poorly organized 
thrombus is visible at the neck remnant interface in aneurysms A and C. Furthermore, the 
neointima and thrombus layers present in aneurysms A and C appear concave, indicating 
some implant compaction. 
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Figure 4.10: Images of H&E stained and sectioned slides from histological analysis 
at various magnification. The top row shows slide images of aneurysm A at 12.5x (A-
12.5x), 40x (A-40x), and 100x (A-100x) magnification. The black arrow indicates the 
eosinophilic SMP foam material, and the white arrow indicates where the Axium coil 
was positioned, though the coil was removed during sectioning. The middle row 
shows slide images of aneurysm B at 12.5x (B-12.5x), 40x (B-40x), and 100x (B-100x) 
magnification. The black arrow indicates the connective tissue within and 
surrounding the coil within the parent artery, and the white arrow indicates the 
endothelial and neointima layer at the interface between the connective tissue in the 
dome and the neck remnant. The bottom row shows slide images of aneurysm C at 
12.5x (C-12.5x), 40x (C-40x), and 100x (C-100x) magnification. The black arrow 
indicates the poorly organized thrombus present at the interface between the 
connective tissue in the dome and the neck remnant. 
 
 
 
Despite the poor packing of the aneurysms, the histological analysis showed 
cellular infiltration and tissue healing within and around the implanted devices that are 
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very promising for achieving stable aneurysm treatment. The desired healing process for 
aneurysm treatment includes thrombus formation with stable fibrin mesh development, 
unextended acute inflammation, T-helper cell guided recruitment of macrophages to break 
down fibrin, and the recruitment of fibroblasts to produce collagen to form granulation 
tissue.71 This healing process progresses from the outer shell of the aneurysm and into the 
central core of the aneurysm. Furthermore, development of a neointima layer across the 
aneurysm neck is also desired to prevent recanalization. The 30-day treated aneurysms 
exhibited dense connective tissue within the outer zone of the aneurysm and loose 
connective tissue within the center of the occluded volumes. The loose connective tissue 
formation within the gaps between implanted materials, as shown in Figure 4.10 (B-40x), 
demonstrates near complete resolution of the fibrin mesh and early formation of 
collagenous tissue. Use of phosphotungstic acid haematoxylin (PTAH) and Masson’s 
trichrome stains in future studies may allow for qualitative and quantitative analysis of the 
residual fibrin and deposited collagen. All aneurysms showed an inflammation response 
led by macrophage activity, primarily in the form of multinucleated giant cells. The 
recruitment of macrophages is a critical component of the healing process, as T-helper 
cells and macrophages can signal an undesired chronic inflammation response or can 
signal continued healing by breaking down fibrin and recruiting fibroblasts. The 
development of loose and dense connective tissues as well as the stable formation of 
multinucleated giant cells around the implanted material indicate that T-helper cells are 
guiding the cellular response towards injury resolution and granulation tissue formation, 
as opposed to the undesired chronic inflammation response. Additionally, the neointima 
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layer formation at the interface between the connective tissue within and around the 
implanted material and the neck remnant is also promising, as this suggests that packing 
of the SMP foam material at or near the aneurysm neck would result in a stable neointima 
formation across the neck. The unorganized thrombus formation can be attributed to 
hemodynamics and recirculation zones expected from the uneven surface of the implanted 
mass. The unorganized thrombus would be expected to be resolved with improved packing 
and prevention of neck remnants. Overall, the inflammation response within the explanted 
aneurysms is very promising and suggests the implant materials have prompted the desired 
healing response; however, longer time-point implants, such as 90-day implants, will be 
required to confirm that the healing process progresses as desired beyond the currently 
tested time-point.  
4.4 Conclusions 
A shape memory polymer (SMP) foam-coated coil (FCC) embolization device was 
designed and demonstrates effective delivery and packing performance for treatment of 
intracranial saccular aneurysms. The FCC device provides clinician-familiar deliverability 
and use combined with great packing volume and scaffolding capability of porous SMP 
foam. Excellent cytocompatibility is a promising early result in showing biocompatibility, 
though several more tests are required to continue assessment of biocompatibility. FCC 
devices exhibited smooth delivery, but difficult packing in both benchtop and rabbit 
elastase aneurysm models highlights the need to improving device stiffness. However, 
though packing in rabbit aneurysms was poor, the tissue response suggests a desired 
healing process and a promising indication that the more effectively packed FCC devices 
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will prompt stable, long-term tissue healing. Overall, this work demonstrates good 
promise for clinical realization of the SMP foam-coated coil embolization device for 
treatment of intracranial saccular aneurysms. 
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CHAPTER V 
CONCLUSIONS 
5.1 Summary 
A shape memory polymer (SMP) foam-coated coil (FCC) neurovascular 
embolization device was designed and developed for treatment of intracranial saccular 
aneurysms. The SMP foam material and device prototypes were characterized and tested 
using various in vitro and in vivo models to evaluate performance and achieve design goals 
of a clinically feasible device. The resulting FCC device provides clinician-familiar 
deliverability and use combined with the large packing volume and tissue scaffolding 
capability of porous SMP foam. 
Solvent-stimulated SMP foam actuation was investigated as a means of achieving 
working time greater than the clinical requirement with the ability to expand the SMP 
foam on demand. Actuation of hydrophobic SMP foams using DMSO and EtOH was 
shown to be an effective alternative shape memory trigger to direct heating. Dramatic 
decreases in Tg were observed with exposure to water, DMSO, and EtOH. EtOH was 
shown to decrease SMP foam relaxation times to less than 1 min in DMA kinetic 
experiments. Furthermore, rapid shape recovery and volume swelling were observed for 
SMP foams in high concentrations of both DMSO and EtOH, as well as in decreased 
concentrations of EtOH. This work demonstrated that both DMSO and EtOH are effective 
at triggering actuation of SMP foams, including in aqueous environments, and that solvent 
selection is critical to the effectiveness of this actuation technique. 
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A SMP foam-over-wire (FOW) neurovascular embolization device was evaluated 
using in vitro and in vivo saccular aneurysm models as an initial prototype design for a 
clinically feasible neurovascular embolization device that implements the advantages of 
SMP foams. FOW devices demonstrated effective delivery and stable implantation in 
vitro. In vivo porcine aneurysms were successfully occluded using FOW devices with 
theoretical volume occlusion values greater than 72% and rapid, stable thrombus 
formation. FOW devices were successful in treating sidewall aneurysm models, though 
the study suggested a need to improve the deliverability and radiopacity of the devices and 
to evaluate the occlusion effectiveness in more clinically relevant aneurysm geometries. 
A SMP foam-coated coil (FCC) embolization device was designed and 
demonstrates effective delivery and repositioning performance for treatment of 
intracranial saccular aneurysms. The FCC device provides clinician-familiar deliverability 
and use combined with large packing density and scaffolding capability of porous SMP 
foam. Excellent cytocompatibility is a promising early result in showing biocompatibility, 
though several more tests are required to continue assessment of biocompatibility. FCC 
devices exhibited smooth delivery, but difficult packing in both benchtop and rabbit 
elastase aneurysm models highlights the need to improving device stiffness. However, 
though packing in rabbit aneurysms was poor, the tissue response suggests a desired 
healing process and a promising indication that the more effectively packed FCC devices 
will prompt stable, long-term tissue healing. Overall, this work demonstrates good 
promise for clinical realization of the SMP foam-coated coil embolization device for 
treatment of intracranial saccular aneurysms. 
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5.2 Significance of Work 
Aneurysmal subarachnoid hemorrhage (aSAH), caused by ruptured intracranial 
aneurysms, results in high morbidity and mortality rates. At least 25% of patients die due 
to aSAH, and approximately 50% of survivors are left with persistent neurological deficit.4 
Standard endovascular treatment of implanting embolization coil devices into saccular 
aneurysms has been shown to be an effective treatment method, but it remains marked by 
aneurysm recanalization or recurrence despite continued development of new device 
technologies.12,13 Aneurysm recurrence or recanalization refer to the return of blood flow 
into an occluded aneurysm and increased risk of rupture and hemorrhage. Early studies of 
bare platinum coils reported recurrence in 21 – 34% of cases.20,21 Based on these 
recurrence rates, polymer-embedded coils were developed with the intent to improve 
healing and reduce recanalization rates. However, new coil technologies have not 
improved recurrence rates, and clinical recurrence remains a primary limitation of 
endovascular coiling, overall occurring in 21% of cases and requiring retreatment in 10% 
of cases.12 
Polyurethane-based shape memory polymer (SMP) foams are advantageous 
biomaterials for endovascular embolization applications due to their shape recovery 
capability and interconnected, large surface area porosity.1,31,32 SMP foams exhibit 
promising cytocompatibility, increased implanted angiographic occlusion, integrated 
connective tissue post-implant, and a thicker neointima layer compared to bare platinum 
coils in porcine saccular aneurysm models.1,31,33 However, previously developed devices 
utilizing SMP foam for neurovascular embolization treatment were limited by required 
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catheter sizes, insufficient flexibility and radiopacity, and inconsistent device stability 
within the aneurysm sac.32  
In chapter II, solvent-stimulated SMP foam actuation was demonstrated as a means 
of achieving working time greater than the clinical requirement with the ability to expand 
the SMP foam on demand. Actuation of hydrophobic SMP foams using DMSO and EtOH 
was shown to be an effective alternative shape memory trigger to direct heating. This work 
was useful in characterizing and improving the expansion behavior of the SMP foams for 
embolization coil application. Though EtOH and DMSO are not ideal solvents for 
neurovascular applications due to moderate to severe toxicological effects, this work 
serves as a proof of concept of SMP foam actuation control using non-water solvents and 
provides insight into mechanisms that can be investigated for future material and device 
design work.46,47 Overall, this work demonstrates great potential for use of solvents as an 
alternative actuation stimulant for polyurethane-based SMP foams and may improve 
feasibility of using SMP materials in a variety of applications. 
In chapter III, a SMP foam-over-wire (FOW) neurovascular embolization device 
demonstrated promising performance in in vitro and in vivo environments as an initial 
prototype design for a clinically feasible neurovascular embolization device. The FOW 
design implemented the SMP foams in a microcatheter-compatible geometry to achieve 
greater volume occlusion than current commercial devices. This device was improved 
upon as discussed in chapter IV, where a SMP foam-coated coil (FCC) embolization 
device demonstrated effective delivery, large packing density, and excellent 
cytocompatibility. Though packing into rabbit aneurysms was difficult, the tissue response 
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suggests a desired healing process and a promising indication that the more effectively 
packed FCC devices will prompt stable, long-term tissue healing. 
Overall, the device designed through this work demonstrates excellent potential 
for improving long-term clinical outcomes for patients with intracranial saccular 
aneurysms, whether ruptured or unruptured. The FFC device enables clinician-familiar 
deliverability that results in implantation of the SMP foam in order to utilize its large 
volume occlusion and improved tissue response, which are promising improvements over 
current commercial devices. This device has the potential to dramatically decrease clinical 
recanalization and recurrence rates, which will reduce the costs and risks associated with 
retreatment or re-rupture, ultimately improving patient outcomes. 
5.3 Challenges and Future Directions 
The SMP foam-coated coil device is a promising candidate for clinical application 
in treatment of intracranial saccular aneurysms. Although the device has demonstrated 
excellent capabilities and properties necessary to meet the needs of the clinician and 
patient, further improvements are required to improve clinical adoption and reduce risks 
of procedural complications. Furthermore, although the characterization and testing 
performed in this work lays a foundation for the device development, more rigorous 
benchtop and animal testing, including within ISO 10993 guidelines, will be required to 
demonstrate device safety and efficacy for clinical application. Additionally, the solvent-
stimulated actuation methodology exhibited promising results, particularly for non-
neurovascular applications, but development of new materials is necessary to allow 
application in the neurovascular environment. 
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Future development of the solvent-stimulated actuation method should focus on 
material design and synthesis that respond to exposure to less toxic substances compared 
to DMSO or EtOH. Perfluorocarbon materials, such as perflourodecalin, 
perflourophenanthrene, or perflouro-n-hexane, have been researched for artificial blood 
applications and therefore are the most desirable for vascular applications as the risks 
associated with injecting these materials are low. Development of a shape memory 
material capable of rapid, controlled actuation in the presence of perfluorocarbons could 
provide complete clinician control over the SMP actuation compared to the current method 
of tailoring the expansion profile with exposure to physiological environments. This 
development would also expand the capabilities of this method into other fields and 
improve overall understanding of the mechanisms of shape memory materials. 
Future development of the FCC device should focus on increasing the device 
flexibility, packing performance, and radiopacity without unduly sacrificing the volume 
occlusion and healing properties of the SMP foam. The current FCC devices demonstrated 
excellent potential in tracking through neurovascular tortuosity and minimal microcatheter 
tip deflection; however, packing the foam-coated coil into small volumes requires 
excessive force and increased risk of vessel perforation, coil migration, or other 
complications. Device flexibility and radiopacity could be improved by decreasing the 
volume of foam coating as well as increasing the coil volume. The SMP foam in its 
compressed state is a stiff material, as a result of achieving the slowed expansion profile 
required for ample clinician working time. Thus, by reducing the overall volume of the 
SMP foam on the coil, the overall stiffness of the device could be improved. However, 
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this will have to be carefully tailored against over performance characteristics, primarily 
working time and packing density. The increase in coil volume is a simple solution for 
improving the fluoroscopic visualization of the device, though this will also have to be 
characterized to ensure that the mechanical stability of the SMP foam on the coil is not 
decreased. 
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